

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0015/13	Ex-vivo evaluation of the surgical specimen by MRI in breast cancer and randomized study comparing MRI and conventional radiography in non-palpable lesions	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0048/14	Health and economic outcomes of two different follow up strategies in effectively cured advanced head and neck cancer	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0024/16	DianaWeb: before and after study online based participatory research to test whether lifestyle and diet are able to reduce the incidence of recurrences (local, remote) or secondary cancers, improve prognosis and survival of breast cancer	Sperimentale non su farmaco	Non applicabile	No Profit	Università degli Studi - Perugia
INT 0151/16	SACral Chordoma: a Randomized & Observational study on surgery versus definitive radiation therapy in primary localized disease (SACRO)	Sperimentale non su farmaco	Non applicabile	No Profit	Italian Sarcoma Group (I.S.G.)
INT 0159/17	Comprehensive geriatric assessment in tailored therapeutic choice for elderly head and neck cancer patients	Sperimentale non su farmaco	Non applicabile	No Profit	Gruppo Oncologico del Nord Ovest (G.O.N.O.)
INT 0108/18	Improving outcome of selected patients with non-resectable hepatic metastases from colo-rectal cancer with liver transplantation: a prospective parallel trial (COLT trial)	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0146/19	Breast cancer T1-T2-T3 / cN +: conservation of axillary lymph nodes in the presence of micrometastases in the sentinel lymph node if cN- after adjuvant chemotherapy	Sperimentale non su farmaco	Non applicabile	No Profit	IRCCS Istituto Clinico Humanitas
INT 0063/20	Isobaric laparoscopic surgery in patients with gynecological malignancies affected by obesity	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0072/20	Immune system activation by electrochemotherapy: hypothesis validating within a prospective study	Sperimentale non su farmaco	Non applicabile	No Profit	A.S.S.T. degli Spedali Civili di Brescia
INT 0152/20	Gait Analysis with surface electromyography in pediatric patients with central nervous system tumor: a preliminary comparative study	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0237/20	Precision Medicine for pediatric tumors (INT-per-Kids)	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0292/20	Randomized multicenter lung cancer screening study with low-dose chest CT (LDCT) associated with primary prevention and comorbidity reduction in high-risk heavy smokers	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0006/21	Organoids from colorectal peritoneal metastases to improve cytoreductive surgery and patient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC).	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0038/21	EIPO Study (Exercise Immunology in Pediatric Oncology): A randomized study to explore the effect of exercise at various intensities on the immune system in children and adolescents with cancer	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0063/21	Eating habits evaluation, metabolomic, immune and microbiota profile in patients with diagnosis of bone sarcoma	Sperimentale non su farmaco	Non applicabile	No Profit	Istituto Ortopedico Rizzoli
INT 0187/21	Impact assessment of an system e-Patient Reported Outcome Measures on home palliative care. Mix-method study of feasibility and intervention.	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0198/21	Prospective clinical trial to assess the utility of a mini-invasive pre-surgical procedure to detect residual disease in the breast or axillary lymph nodes in patients with cT1-cT2-cT3 cN0/cN1 breast cancer in complete clinical/radiological remission after primary chemotherapy.	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0267/21	A multicentre randomised trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0001/22	Integrating the Fundamentals of Care Framework into (Italian) Nursing Education (Fundamental4Education)	Sperimentale non su farmaco	Non applicabile	No Profit	Università degli Studi di Genova
INT 0024/22	Get Strong to Fight Childhood Cancer: An Exercise Intervention for Children and Adolescents Undergoing Anti-Cancer Treatment (FORTee)	Sperimentale non su farmaco	Non applicabile	No Profit	Childhood Cancer Center
INT 0069/22	IDENTIFICATION OF CIRCULATING MARKERS TO CUSTOMIZE THE FOLLOW-UP OF HEAD AND NECK CANCER PATIENTS FOR EARLY DETECTION OF RECURRENCES/SECOND PRIMARIES	Sperimentale non su farmaco	Non applicabile	No Profit	A.S.S.T. degli Spedali Civili di Brescia
INT 0168/22	Ovarian cancer screening in high-risk women with family history or suggestive symptoms (EUGENIA STUDY)	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0182/22	4-IN-THE-LUNG-RUN (Towards individually tailored INvitations, screening Intervals, and Integrated co-morbidity reducing strategies in lung cancer screening): A Randomised Comparison of Personalised Lung Cancer Screening Regimens (4-ITLR)	Sperimentale non su farmaco	Non applicabile	No Profit	Erasmus University Medical Center - Rotterdam (NL)
INT 0206/22	"APPROACH study: Multimodal approach in patients with mHSPC. A pragmatic randomized trial and local treatment	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0207/22	FASTing-like approach to improve the efficacy of maintenance IMMUnotherapy in Extensive-stage small cell lung cancer patients not progressing on chemoimmunotherapy induction: the FASTIMMUNE trial	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0214/22	Targeting triple negative BREASt cancer metabolism with a combination of chemoimmunotherapy and a diet mimicking FASTing in the preoperative setting: the BREAKFAST 2 trial	Sperimentale non su farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0092/23	High versus STandard blood Pressure target in hypertensive high-risk patients undergoing elective major abdominal surgery: The HISTAP randomized clinical trial	Sperimentale non su farmaco	Non applicabile	No Profit	SIAARTI (Società Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva)
INT 0107/23	A randomised effectiveness-implementation trial for evaluating dietary and manual treatment with osteopathic techniques on quality of life and on modulation of the inflammatory state of patients diagnosed with breast cancer undergoing antiestrogenic hormonal treatment.	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0142/23	Effects of maintenance of motor and respiratory performance with a training program during hospitalization in patients undergoing CAR-T cell therapy	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0145/23	Treatment of Oligometastatic breast cancer – a randomised phase 3 trial comparing stereotactic ablative radiotherapy and systemic treatment with systemic treatment alone as 1st line treatment TAORMINA	Sperimentale non su farmaco	III	No Profit	Swedish Association of Breast Oncologists (SABO),
INT 0254/23	A multi cohort translational research study to investigate mechanisms of resistance to breast cancer therapies	Sperimentale non su farmaco	Non applicabile	Profit	F. Hoffmann-La Roche, Ltd
INT 0280/23	Radiomics and Radiogenomics models to predict molecular-integrated risk classes and prognostic factors in endometrial cancer.	Sperimentale non su farmaco	Non applicabile	No Profit	Policlinico Universitario Gemelli (RM)
INT 0023/24	Integrated Short-term Palliative Rehabilitation to improve quality of life and equitable care access in incurable cancer: A multi-national randomised controlled trial	Sperimentale non su farmaco	Non applicabile	No Profit	King's College London
INT 0053/24	PROMOTE: Home-based monitoring of adverse events and quality of life in patients with mCRC treated with anti-VEGF drugs using PROACT 2.0	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0111/24	User experience study of digital tools to collect data on wellbeing and side effects in cancer patients	Sperimentale non su farmaco	Non applicabile	No Profit	Netherlands Cancer Institute
INT 0072/13	Predictive models of genito-urinary toxicity and erectile dysfunction after external high dose radiotherapy for prostate cancer	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0161/13	Modulazione del Sistema Immunitario e Chemioterapia Adiuvante nel carcinoma mammario	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0054/16	Comparison between protective and non restrictive diet in oncological patients with prolonged neutropenia	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0091/16	Application of a perioperative nutritional and hemodynamic protocol in patients with retroperitoneal sarcomas. A feasibility study	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0078/17	Preventive anti-inflammatory diet to reduce gastro-intestinal inflammation in Familial Adenomatous Polyposis (FAP) patients: a prospective pilot study	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0114/17	Trial on radical upfront surgery in advanced ovarian cancer	Sperimentale non su farmaco	Non applicabile	No Profit	AGO Research GmbH
INT 0042/20	Feasibility study for the joint genomic diagnosis of genetic risk and sensitivity to new drugs in breast, ovarian and colorectal tumors	Sperimentale non su farmaco	Non applicabile	No Profit	Alleanza Contro il Cancro
INT 0160/22	Pilot study on the efficacy of smoking cessation interventions in women candidates for breast cancer surgery	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0082/24	Partial Radiotherapy for breast In Situ Carcinoma of Intermediate Low risk as Local Adjuvant treatment - PRISCILLA study	Sperimentale non su farmaco	II	No Profit	IRCCS Istituto Clinico Humanitas
INT 0098/12	PASS Pleural mesothelioma Strategies Study	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0233/20	E-health solution for follow-up management of patients on Active Surveillance	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0279/20	Fluorescence-based augmented reality in oncologic surgery with indocyanine green injection - GREENEYE Study	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0196/21	Evaluation of post-operative pain in patients undergone inframammary fold reconstruction within implant-based breast reconstruction	Sperimentale non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0016/03	Germ cell tumors: diagnostic-therapeutic protocol AIEOP 2003	Sperimentale con farmaco	III	No Profit	Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)
INT 0038/10	Tandem transplantation of autologous hematopoietic progenitors in relapsed/refractory patients with metastatic germinal tumors	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0014/15	An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma	Sperimentale con farmaco	II/III	No Profit	Centre Léon Bérard, France
INT 0064/15	Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus Radiotherapy in Soft Tissue Sarcoma patients	Sperimentale con farmaco	I/II	No Profit	Grupo Español de Investigación en Sarcomas (GEIS)
INT 0091/15	International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma	Sperimentale con farmaco	II/III	No Profit	Università di Birmingham
INT 0185/15	LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis	Sperimentale con farmaco	III	No Profit	St. Anna Kinderkrebsforschung/CCRI
INT 0047/17	International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma	Sperimentale con farmaco	II/III	No Profit	Università di Birmingham
INT 0142/17	An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib	Sperimentale con farmaco	IV	Profit	Novartis Farma S.p.A.
INT 0037/18	A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC	Sperimentale con farmaco	II	No Profit	IRCCS "Fondazione Pascale" (NA)
INT 0063/18	A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)	Sperimentale con farmaco	I	Profit	LOXO ONCOLOGY INCORPORATED
INT 0107/18	Multicenter randomized open-label phase III trial of Adjuvant Chemotherapy plus mitotane vs. mitotane after primary surgical resection of localized Adrenocortical Carcinoma with high risk of recurrence	Sperimentale con farmaco	III	No Profit	A.O. Spedali Civili di Brescia
INT 0155/18	Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumor	Sperimentale con farmaco	I	Profit	TESARO Inc.
INT 0161/18	Long-term follow-up protocol for subjects treated with gene-modified T cells	Sperimentale con farmaco	III	Profit	Celgene Corporation
INT 0178/18	Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance in untreated patients with Activated-B-Cell (ABC)-DLBCL at intermediate-high and high risk (IPI ≥2)	Sperimentale con farmaco	II	No Profit	Fondazione Italiana Linfomi (FIL)
INT 0180/18	Cabozantinib plus Ddurvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-of-concept trial: ARCADIA study	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0196/19	A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	Sperimentale con farmaco	I/II	Profit	Turning Point Therapeutics, Inc.
INT 0197/19	An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants	Sperimentale con farmaco	I/II	Profit	Incyte Biosciences International
INT 0240/19	A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0001/20	A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)	Sperimentale con farmaco	III	Profit	Eli Lilly & Company, Lilly Corporate Center
INT 0003/20	A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC)(KEYNOTE-992)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme S.p.A
INT 0068/20	Phase II study of adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the prevention of peritoneal metastases after curative-intent surgery for high-risk colorectal cancer	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0069/20	European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors - ESMART	Sperimentale con farmaco	I/II	No Profit	Istituto Gustave-Roussy di Parigi
INT 0073/20	A Phase 1/2, Multicentre, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Naldemedine in Paediatric Patients Who Are Receiving or Who Are About to Receive Treatment with Opioids	Sperimentale con farmaco	I/II	Profit	Shionogi B.V.
INT 0151/20	Phase 1b trial of 5-fluorouracil, leucovorin, irinotecan in combination with temozolomide (FLIRT) and bevacizumab for the first-line treatment of patients with MGMT silenced, microsatellite stable metastatic colorectal cancer	Sperimentale con farmaco	I	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0187/20	A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma	Sperimentale con farmaco	III	No Profit	EORTC (European Organisation for Research and Treatment Cancer)

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0210/20	Personalized therapy of metastatic thyroid cancer: biological characterization and optimization with 124I PET dosimetry	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0289/20	A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (TDXd) Monotherapy and Combinations in Adult Participants with HER2 Overexpressing Gastric Cancer (DESTINY-Gastric03)	Sperimentale con farmaco	I/II	Profit	AstraZeneca S.p.A.
INT 0003/21	Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuvant chemotherapy: the ERASE-TMZ study	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0007/21	Tumor-agnostic precision immunooncology and somatic targeting rational for you (TAPISTRY) phase II platform trial	Sperimentale con farmaco	II	Profit	Roche S.p.A.
INT 0028/21	ExclUusive endocRine therapy Or radiation theraPy for women aged ≥70 years with luminal A-like early stage breast cancer (EUROPA): a randomized phase 3 trial	Sperimentale con farmaco	III	No Profit	Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Università degli Studi - Firenze
INT 0033/21	High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEP)	Sperimentale con farmaco	III	No Profit	Istituto Gustave-Roussy di Parigi
INT 0039/21	Phase II study on Trabectedin in advanced rearranged Mesenchymal chondrosarcoma (MCS)	Sperimentale con farmaco	II	No Profit	Italian Sarcoma Group (I.S.G.)
INT 0065/21	Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS mutated in Liquid Biopsy to compare in first-line therapy FOLFIRI plus Cetuximab or Bevacizumab	Sperimentale con farmaco	III	No Profit	Azienda USL-IRCCS di Reggio Emilia
INT 0066/21	TUMOR-AGNOSTIC PRECISION IMMUNOONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL	Sperimentale con farmaco	II	Profit	Roche S.p.A.
INT 0067/21	A phase-II academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or nivolumab in relapsed or refractory classical Hodgkin lymphoma (CHL)	Sperimentale con farmaco	II	No Profit	DIPARTIMENTO DI MEDICINA E CHIRURGIA DELL'UNIVERSITÀ DEGLI STUDI DI PERUGIA
INT 0092/21	A phase I/II, open-label, multicenter study evaluating the safety, pharmacokinetics, and efficacy of alectinib in pediatric patients with alk fusion positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory treatment available	Sperimentale con farmaco	I/II	Profit	F. Hoffmann-La Roche, Ltd
INT 0105/21	A Randomized & Observational phase II trial assessing the activity of Trabectedin vs gemcitabine in patients with metastatic or locally advanced Leiomyosarcoma pretreated with conventional chemotherapy	Sperimentale con farmaco	II	No Profit	Italian Sarcoma Group (I.S.G.)
INT 0122/21	Randomized study to protect from radiation iatrogenic hypothyroidism patients with medulloblastoma (any age, stage and any biological risk) and pediatric patients with hodgkin lymphoma and non-hodgkin lymphoma needing radiation therapy on thyroid site	Sperimentale con farmaco	III	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0129/21	A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies. Study ITCC 053	Sperimentale con farmaco	I/II	No Profit	Erasmus Medical Cancer Center
INT 0130/21	LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma	Sperimentale con farmaco	III	No Profit	Ospedale Universitario di Munster - Germania
INT 0157/21	An International Prospective Trial on High-Risk Medulloblastoma in Patients Older than 3 Years	Sperimentale con farmaco	III	No Profit	University of Birmingham
INT 0173/21	A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK- 3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0188/21	Multicenter phase II study of preoperative chemoradiotherapy with CApecitabine plus Temozolomide in patients with MGMT silenced and microsatellite stable locally Advanced RecTal Cancer: the CATARTIC trial	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0191/21	A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03)	Sperimentale con farmaco	I	Profit	AstraZeneca AB
INT 0192/21	Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumors.	Sperimentale con farmaco	II	No Profit	Vall d'Hebron Institute of Oncology
INT 0200/21	Phase II, multicenter, randomized, open-label study with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcoma	Sperimentale con farmaco	II	No Profit	Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)
INT 0201/21	An open-label, single-arm, phase Ib/IIa trial to evaluate the safety and efficacy of the EP4 receptor antagonist CR6086 in combination with the PD-1 inhibitor balstilimab (AGEN2034), in patients with pretreated mismatch-repair-proficient and microsatellite stable metastatic colorectal cancer.	Sperimentale con farmaco	I/II	Profit	Rottapharm Biotech S.r.l.
INT 0221/21	EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HRpositive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor	Sperimentale con farmaco	III	Profit	Novartis Farma S.p.A.
INT 0245/21	Immune checkpoint inhibitors and Carbon ION radiotherapy in solid Cancers with stable disease (ICONIC)	Sperimentale con farmaco	II	No Profit	Fondazione CNAO Centro Nazionale di Adroterapia Oncologica
INT 0264/21	A Phase I/IIa, Multicenter, Open-Label Study of NvS-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors	Sperimentale con farmaco	I/II	Profit	NOUSCOM SRL
INT 0002/22	Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0004/22	A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0005/22	A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab in Participants with Advanced Solid Tumors	Sperimentale con farmaco	I/II	Profit	Bristol-Myers Squibb International Corporation
INT 0008/22	A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma	Sperimentale con farmaco	II	Profit	Inhibrx
INT 0025/22	AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER SPONSORED AVELUMAB CLINICAL STUDIES	Sperimentale con farmaco	II	Profit	Pfizer Inc.

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0036/22	A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy - ARTISTRY-6	Sperimentale con farmaco	II	Profit	ALKERMES
INT 0060/22	A Single-Arm, Open-label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Talrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors	Sperimentale con farmaco	II	Profit	AnHeart Therapeutics Inc
INT 0065/22	Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0097/22	A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma	Sperimentale con farmaco	III	Profit	Kite Pharma, Inc.
INT 0111/22	A phase I/II, open-label, multi-cohort study to evaluate the efficacy and safety of CEVOSTAMAB in prior B cell maturation antigen-exposed patients with relapsed/refractory multiple myeloma	Sperimentale con farmaco	I/II	Profit	F. Hoffmann-La Roche, Ltd
INT 0113/22	An adaptive first-in-human trial of PhOx430, a first-in-class acetylglucosaminyltransferase V inhibitor, in patients with Advanced Solid Tumours	Sperimentale con farmaco	I	Profit	Phost'in Therapeutics SAS
INT 0114/22	A Phase 1, Open-label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors	Sperimentale con farmaco	I	Profit	Incyte Corporation
INT 0119/22	Exploiting circulating tumour dna to intensify the post-operative treatment of stage III and high-risk stage II resected colon cancer patients with ADJUVANT FOLFOXIRI AND/OR POST-ADJUVANT TRIFLURIDINE/TIPRACIL	Sperimentale con farmaco	II	No Profit	Fondazione GONO
INT 0120/22	An open label, multi-center roll-over study to assess long-term effect in pediatric patients treated with Tafinlar (dabrafenib) and/or Mekinist (trametinib)	Sperimentale con farmaco	IV	Profit	Novartis Pharma AG
INT 0138/22	Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma	Sperimentale con farmaco	II/III	Profit	Boehringer Ingelheim Italia S.p.A.
INT 0158/22	Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblastoma and other solid tumors	Sperimentale con farmaco	I/II	Profit	Novartis Pharma AG
INT 0159/22	Window-of-opportunity study of chemo-immunotherapy in patients with resectable Merkel Cell Carcinoma prior to surgery: the MERCURY trial	Sperimentale con farmaco	II	No Profit	Fondazione GONO
INT 0163/22	A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian Cancer Following a Front-Line Complete Cytoreductive Surgery	Sperimentale con farmaco	II	No Profit	ARCAGY-GINECO
INT 0181/22	A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)	Sperimentale con farmaco	III	Profit	Zymeworks Inc.
INT 0192/22	Neoadjuvant pembrolizumab in high-risk thyroid cancers (NEPENTHE)	Sperimentale con farmaco	II	No Profit	Istituti Clinici Scientifici Maugeri SpA SB
INT 0193/22	Restoring sensitivity to immunotherapy in advanced triple negative breast cancer exploiting Ceralasertib priming followed by combined Durvalumab/Nab-paclitaxel: The ATRIBRAVE Trial.	Sperimentale con farmaco	II	No Profit	IFOM - Fondazione Istituto FIRC di Oncologia Molecolare
INT 0195/22	A first-in-human (FIH) study of IDRx-42 in participants with metastatic and/or unresectable gastrointestinal stromal tumors (GIST)	Sperimentale con farmaco	I	Profit	IDRx
INT 0196/22	An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK- 3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0208/22	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1	Sperimentale con farmaco	III	Profit	Gilead Sciences, Inc
INT 0209/22	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1.	Sperimentale con farmaco	III	Profit	Gilead Sciences, Inc
INT 0211/22	A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PvD) or Carfilzomib,Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide	Sperimentale con farmaco	III	Profit	Janssen-Cilag SpA
INT 0001/23	LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy	Sperimentale con farmaco	III	Profit	Day One Biopharmaceuticals
INT 0002/23	Use of LOncastuximab Tesirine in patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High Grade B-Cell Lymphoma (HGBCL) who have progressive disease after CAR T-cell treatment - LORELY	Sperimentale con farmaco	II	No Profit	IRCCS Istituto Clinico Humanitas
INT 0004/23	A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of- Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer	Sperimentale con farmaco	I/II	Profit	Janssen-Cilag International NV
INT 0022/23	A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress with First Line Platinum-Containing Chemotherapy	Sperimentale con farmaco	II	Profit	Merck KGaA
INT 0027/23	An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as Firstline Treatment for Subjects with HER2+ Metastatic Colorectal Cancer	Sperimentale con farmaco	III	Profit	Seagen Inc

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0028/23	A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, METOverexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)	Sperimentale con farmaco	III	Profit	AstraZeneca AB
INT 0045/23	A phase II study of L191L2/L19TNF in patients with skin cancers amenable to intralesional treatment	Sperimentale con farmaco	II	Profit	Philogen S.p.A.
INT 0046/23	A phase Ib/II, open-label, multicenter study evaluating the safety, activity, and pharmacokinetics OF GDC-6036 in combination with other anti-cancer therapies in patients with previously untreated advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation	Sperimentale con farmaco	I/II	Profit	F. Hoffmann-La Roche, Ltd
INT 0054/23	A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)	Sperimentale con farmaco	I/II	Profit	Nuvalent Inc.
INT 0056/23	A phase III, single-arm study to evaluate the efficacy and safety of ONCOFID-P-B (paclitaxel-hyaluronic acid conjugate) administered intravesically to patients with BCGunresponsive Carcinoma in Situ of the bladder with or without Ta-T1 papillary disease	Sperimentale con farmaco	III	Profit	FIDIA FARMACEUTICI S.P.A.
INT 0061/23	An Italian multicenter phase II trial of Metronomic Temozolomide in unfit patients with advanced neuroendocrine neoplasms (NENs): MeTe study	Sperimentale con farmaco	II	No Profit	Istituto Europeo di Oncologia
INT 0067/23	A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA)	Sperimentale con farmaco	I/II	Profit	AstraZeneca AB
INT 0070/23	Efficacy of Perioperative Pembrolizumab treatment in patients with resectable metastases from kidney cancer. The PE-PE study.	Sperimentale con farmaco	II	No Profit	CONSORZIO ONCOTECH
INT 0109/23	Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)	Sperimentale con farmaco	II/III	Profit	IMMUNOCORE LTD
INT 0110/23	A phase I, open label, multi-center study of KFA115 as a single agent and in combination with tislelizumab in patients with selected advanced cancers	Sperimentale con farmaco	I	Profit	Novartis Pharma AG
INT 0114/23	A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors	Sperimentale con farmaco	I	Profit	Incyte Corporation
INT 0118/23	WINDOW-OF-OPPORTUNITY UMBRELLA PLATFORM TRIAL OF SHORT-COURSE PRE-OPERATIVE TARGETED TREATMENTS IN PATIENTS WITH MOLECULARLY SELECTED AND RESECTABLE PRIMARY COLORECTAL CANCER: THE UNICORN STUDY	Sperimentale con farmaco	II	No Profit	Fondazione GONO
INT 0119/23	A phase II/III randomized clinical trial of CisPlatin pLUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patients with resectable Biliary Tract Cancers (BTC) at high risk for recurrence: PURITY Study	Sperimentale con farmaco	II/III	No Profit	Fondazione GONO
INT 0121/23	Akynzeo as antiemetic treatment in patients with endometrial cancer treated with taxane - platinum combination chemotherapy. NOEME study	Sperimentale con farmaco	IV	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0122/23	Circulating microRNAs to choose the IO strategy in PD-L1=50% NSCLC patients: the Ark clinical trial	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0123/23	A Phase II study evaluating efficacy of KTE-X19 CAR-T cell therapy in Relapsed or Refractory Mantle-Cell Lymphoma achieving a partial response during Ibrutinib salvage therapy	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0124/23	A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, phase Ib/II trial NICHOL TRIAL	Sperimentale con farmaco	I/II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0157/23	A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreak 202).	Sperimentale con farmaco	III	Profit	Amgen S.r.l
INT 0158/23	Phase II, open label, single arm study of Pembrolizumab combined with cisplatin or carboplatin and etoposide in treatment naive advanced merkel cell carcinoma (MCC)	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0162/23	An open-label, randomized phase III trial comparing local radiotherapy alone or combined with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial from the Fondazione Italiana Linfomi	Sperimentale con farmaco	III	No Profit	Fondazione Italiana Linfomi (FIL)
INT 0166/23	AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED AVELUMAB CLINICAL STUDIES. SUB-STUDY: AN OPEN-LABEL STUDY FOR CONTINUED TREATMENT ACCESS FOR PARTICIPANTS FROM THE B9991003 AVELUMAB STUDY	Sperimentale con farmaco	IV	Profit	Pfizer Inc.
INT 0190/23	Venetoclax and delayed rituximab with ibrutinib consolidation aiming at undetectable minimal residual disease (uMRD) in treatment-naïve patients with chronic lymphocytic leukemia (CLL) VALUABLE	Sperimentale con farmaco	II	No Profit	San Raffaele
INT 0192/23	A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme S.p.A
INT 0193/23	Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer	Sperimentale con farmaco	II	Profit	Gilead Sciences, Inc
INT 0194/23	Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies.	Sperimentale con farmaco	I/II	Profit	Bicycle
INT 0196/23	A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1) NVL-655-01	Sperimentale con farmaco	I/II	Profit	Nuvalent Inc.
INT 0197/23	Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravantsine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRA-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)	Sperimentale con farmaco	III	Profit	Immunogen Inc
INT 0200/23	A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma	Sperimentale con farmaco	I/II	Profit	Alentis Therapeutics AG
INT 0213/23	Efficacy and safety of frontline tislelizumab in patients with de novo Hodgkin lymphoma unsuitable for standard frontline chemotherapy: a phase II, open-label study	Sperimentale con farmaco	II	No Profit	Fondazione Italiana Linfomi (FIL)

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0215/23	An open-label, multi-center, Phase I study of oral IAG933 in adult patients with advanced Mesothelioma and other solid tumors	Sperimentale con farmaco	I	Profit	Novartis Farma S.p.A.
INT 0223/23	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB IN COMBINATION WITH PHESGO VERSUS PLACEBO IN COMBINATION WITH PHESGO AS MAINTENANCE THERAPY AFTER FIRST LINE INDUCTION THERAPY IN PARTICIPANTS WITH PIK3CA MUTATED HER2 POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER	Sperimentale con farmaco	III	Profit	Roche S.p.A.
INT 0224/23	IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2)	Sperimentale con farmaco	II	Profit	IDEAYA Biosciences
INT 0231/23	A PHASE III RANDOMIZED, OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT, BOTH COMBINED WITH A CDK4/6 INHIBITOR, IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY	Sperimentale con farmaco	III	Profit	F. Hoffmann-La Roche, Ltd
INT 0233/23	Adjuvant Trastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after preoperative chemotherapy and radical surgery: the TRINITY study.	Sperimentale con farmaco	II	No Profit	Fondazione GONO
INT 0234/23	A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)	Sperimentale con farmaco	III	Profit	AstraZeneca S.p.A.
INT 0247/23	A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater than or Equal to 50%	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme S.p.A
INT 0251/23	A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme S.p.A
INT 0266/23	A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck	Sperimentale con farmaco	II	Profit	GlaxoSmithKline S.p.A.
INT 0269/23	A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)	Sperimentale con farmaco	III	Profit	Duality
INT 0277/23	A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme S.p.A
INT 0278/23	Phase 2 Study of Neoadjuvant Pembrolizumab with Platinum Doublet+V940 Followed by Surgery and Adjuvant pembrolizumab W/WO V940 in Resectable Stages II-IIIb(N2) NSCLC." The study manager for this CTT, Shady Prestol, will be reaching out to you or your CRM for study related activities if your country is on the PVCL	Sperimentale con farmaco	II	Profit	Merck Sharp & Dohme S.p.A
INT 0279/23	A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme S.p.A
INT 0293/23	A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK2870-005/ENGOT-en23/GOG-3095)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme S.p.A
INT 0001/24	A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer	Sperimentale con farmaco	III	Profit	Seagen Inc
INT 0002/24	A MULTI-CENTER PHASE 2 STUDY OF NEOADJUVANT IMMUNOTHERAPY IN COMBINATION WITH THE ANTI-GDF-15 ANTIBODY VISUGROMAB (CTL-002) FOR THE TREATMENT OF MUSCLE INVASIVE BLADDER CANCER	Sperimentale con farmaco	II	Profit	Catalym
INT 0036/24	MK-9999-02A Substudy: A Phase 1/2 Substudy of the MK-9999-002 Master Protocol to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers	Sperimentale con farmaco	I/II	Profit	Merck Sharp & Dohme S.p.A
INT 0038/24	A Phase 3, Multicenter, Open-label, randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme S.p.A
INT 0044/24	A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (V940-004-00)	Sperimentale con farmaco	II	Profit	Merck Sharp & Dohme S.p.A
INT 0045/24	A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)	Sperimentale con farmaco	III	Profit	Astrazeneca
INT 0046/24	Open-label, non-randomized, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of S095029 (anti- NKG2A antibody) as a part of combination therapy in participants with locally advanced and unresectable or metastatic MSIH/dMMR gastroesophageal junction /gastric cancer	Sperimentale con farmaco	I/II	Profit	Institut de Recherches Internationales Servier

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0047/24	IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 8/? Alone or in Combination with Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination with Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants with Locally Advanced or Metastatic Solid Tumor Malignancies	Sperimentale con farmaco	I/II	Profit	Ascendis Pharma Oncology
INT 0073/24	A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy–Sunrise 4	Sperimentale con farmaco	II	Profit	Janssen-Cilag SpA
INT 0076/24	A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme S.p.A
INT 0106/24	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rivegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)	Sperimentale con farmaco	III	Profit	AstraZeneca AB
INT 0108/24	An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer	Sperimentale con farmaco	III	Profit	Jazz Pharmaceuticals
INT 0142/24	A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations	Sperimentale con farmaco	III	Profit	Janssen-Cilag International NV
INT 0143/24	A phase 3, randomized, open-label, multi center study evaluating the efficacy and safety of TAR-200 versus Investigator's choice of intravesical chemotherapy in participants who received Bacillus Calmette-Guérin (BCG) and recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and who are ineligible for or elected not to undergo radical cystectomy	Sperimentale con farmaco	III	Profit	Janssen-Cilag International NV
INT 0147/24	An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme S.p.A
INT 0148/24	A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme S.p.A
INT 0187/24	SINGLE ARM PHASE II STUDY OF ctDNA-GUIDED ENCORA-FENIB PLUS CETUXIMAB RETREATMENT IN PATIENTS WITH BRAFV600E MUTATED mCRC	Sperimentale con farmaco	II	No Profit	Fondazione GONO
INT 0188/24	Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left sided RAS/B-RAF wild-type metastatic colorectal cancer (IMPROVE-2 trial)	Sperimentale con farmaco	III	No Profit	IRCCS "Fondazione Pascale" (NA)
INT 0040/01	Protocol NB-AR-01: First European Cooperative Study for high-risk neuroblastoma	Sperimentale con farmaco	III	No Profit	St. Anna Kinderkrebsforschung/CCRI
INT 0062/11	First International Inter-Group Sydlu for nodular lymphocyte-predominant Hodgkin's Lymphoma in Children and Adolescents	Sperimentale con farmaco	IV	No Profit	AIEOP e Martin-Luther-University of Halle/Wittenberg, Germany
INT 0043/12	European Low an Intermediate Risk Neuroblastoma	Sperimentale con farmaco	III	No Profit	Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)
INT 0028/13	Multidisciplinary approach for poor prognosis sinonasal tumors: phase II study of chemotherapy, surgery, photon and heavy ion radiotherapy integration for more effective and less toxic treatment in operable patients	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0029/13	Multidisciplinary approach for poor prognosis sinonasal tumors: Phase II study of chemotherapy, photon and heavy ion radiotherapy integration for more effective and less toxic treatment in inoperable patients	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0083/13	A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma	Sperimentale con farmaco	III	Profit	Millennium Pharmaceuticals Inc.
INT 0125/13	A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy	Sperimentale con farmaco	III	Profit	AstraZeneca S.p.A.
INT 0175/13	AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB – LR and PNET 5 MB – WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB – SR), OR TP53 MUTATION, AND REGISTRY FOR MB OCCURRING IN THE CONTEXT OF GENETIC PREDISPOSITION	Sperimentale con farmaco	II/III	No Profit	University Medical Center Hamburg-Eppendorf
INT 0087/14	Romidepsin in combination with Choep as first line treatment before hematopoietic stem cell transplantation in young patients with nodal peripheral T-cell lymphomas: a phase I-II study	Sperimentale con farmaco	I/II	No Profit	Fondazione Italiana Linfomi (FIL)
INT 0171/14	A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma	Sperimentale con farmaco	III	Profit	Bristol-Myers Squibb S.r.l.
INT 0040/15	A multicenter, randomized, open label phase II study of carfilzomib, cyclophosphamide and dexamethasone (CCyd) as pre transplant induction and post transplant consolidation or carfilzomib, lenalidomide and dexamethasone (CRd) as pre transplant induction and post transplant consolidation or continuous treatment with carfilzomib, lenalidomide and dexamethasone (12 cycles) without transplant, all followed by maintenance with lenalidomide (R) versus lenalidomide and carfilzomib (CR) in newly diagnosed Multiple Myeloma (MM) patients eligible for autologous transplant	Sperimentale con farmaco	II	No Profit	Università degli Studi di Torino
INT 0078/15	A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemioimmunotherapy with Rituximab-Bendamustine for relapsed/refractory FL patients not eligible for autologous transplantation (ASCT)	Sperimentale con farmaco	III	No Profit	Fondazione Italiana Linfomi (FIL)
INT 0180/15	Safety of Lanreotide 120 mg ATG in combination with Metformin in patients with progressive advanced Well-differentiated gastro-intestinal (GI) or lung carcinoids	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0190/15	A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0042/16	Adjuvant treatment for high-risk triple negative breast cancer patients with the anti-PD-L1 antibody avelumab: a phase III randomized trial	Sperimentale con farmaco	III	No Profit	Università degli Studi - Padova
INT 0045/16	A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy	Sperimentale con farmaco	II	Profit	Merck Sharp & Dohme Corporation
INT 0046/16	A randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by High-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumours	Sperimentale con farmaco	III	No Profit	EORTC (European Organisation for Research and Treatment Cancer)
INT 0048/16	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Sperimentale con farmaco	II	Profit	Ignity Operating INC
INT 0052/16	Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing Nilotinib versus Imatinib with switch to Nilotinib in absence of optimal response	Sperimentale con farmaco	IV	No Profit	Fondazione GIMEMA Onlus
INT 0067/16	A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma	Sperimentale con farmaco	III	Profit	Bristol-Myers Squibb International Corporation
INT 0083/16	A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0110/16	A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in combination with Tremelimumab or Bevacizumab in Subjects with Advanced Hepatocellular Carcinoma.	Sperimentale con farmaco	I	Profit	MedImmune LCC
INT 0175/16	A phase II trial addressing feasibility and activity of clarithromycin + lenalidomide combination: a full oral treatment for patients with relapsed/refractory extranodal mucosa-associated lymphoid tissue (MALT) lymphoma (CLEO Study)	Sperimentale con farmaco	II	No Profit	IELSG (INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP)
INT 0049/17	A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors	Sperimentale con farmaco	I/II	Profit	Bayer AG
INT 0065/17	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme S.p.A
INT 0083/17	A Multi-Center, Open Label, Uncontrolled, Phase 2a Clinical Trial Evaluating the Safety and Efficacy of the Addition of Ibrutinib to Venetoclax through a MRDguided Approach in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia (CLL)	Sperimentale con farmaco	II	No Profit	Ospedale San Raffaele IRCCS
INT 0116/17	A Phase 3, randomized, open-label study of lorlatinib (PF-06463922) monotherapy versus crizotinib monotherapy in the first-line treatment of patients with advanced ALK-positive non-small cell lung cancer	Sperimentale con farmaco	III	Profit	Pfizer Inc.
INT 0129/17	A randomized trial of multifactorial primary prevention in high risk subjects candidate to a lung cancer early detection CT program	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0131/17	Phase 3, Open-label, Randomized Study of Nivolumab Combined with pili mumab versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer	Sperimentale con farmaco	III	Profit	Bristol-Myers Squibb International Corporation
INT 0143/17	A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme S.p.A
INT 0156/17	A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma	Sperimentale con farmaco	III	Profit	ADVENCHEN LABORATORIES, LLC
INT 0210/17	Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas	Sperimentale con farmaco	I/II	No Profit	Grupo Español de Investigación en Sarcomas (GEIS)
INT 0003/18	A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0005/18	A Phase III, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation (CheckMate 9DX: CHECKpoint pathway and nivolumab clinical Trial Evaluation 9DX)	Sperimentale con farmaco	III	Profit	Bristol-Myers Squibb International Corporation
INT 0039/18	Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer	Sperimentale con farmaco	III	No Profit	Fondazione Michelangelo
INT 0041/18	Phase 2 open label study of CaBozantinib in patients with advanced or unresectable Renal cEl carcinoma pretreated with one immunocheckPOINT Inhibitor (anti PD1/PDL1): the BREAKPOINT trial	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0053/18	Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL)	Sperimentale con farmaco	II	No Profit	Fondazione Italiana Linfomi (FIL)
INT 0062/18	A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated	Sperimentale con farmaco	II/III	Profit	Bristol-Myers Squibb International Corporation
INT 0134/18	Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme S.p.A
INT 0160/18	Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer	Sperimentale con farmaco	III	Profit	AstraZeneca AB
INT 0163/18	Pembrolizumab in mmmr-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status. The arethusa trial	Sperimentale con farmaco	II	No Profit	IFOM - Fondazione Istituto FIRC di Oncologia Molecolare

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0179/18	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)	Sperimentale con farmaco	III	Profit	MSD Italia Srl
INT 0193/18	A MULTICENTER, OPEN-LABEL, PHASE I/II STUDY TO EVALUATE THE SAFETY, EFFICACY, TOLERABILITY AND PHARMACOKINETICS OF ESCALATING DOSES OF GLOFITAMAB (RO7082859) AS A SINGLE AGENT AND IN COMBINATION WITH OBINUTUZUMAB ADMINISTERED AFTER A FIXED, SINGLE DOSE PRE-TREATMENT OF OBINUTUZUMAB (GAZYVA2/GAZYVARO?) IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON?HODGKIN'S LYMPHOMA	Sperimentale con farmaco	I	Profit	F. Hoffmann-La Roche, Ltd
INT 0194/18	A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small Cell- Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)	Sperimentale con farmaco	III	Profit	AstraZeneca S.p.A.
INT 0201/18	Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer	Sperimentale con farmaco	II	No Profit	Gruppo Oncologico del Nord Ovest (G.O.N.O.)
INT 0018/19	Carfilzomib - Lenalidomide - Dexamethasone (KRD) versus Lenalidomide - Dexamethasone (ERD) in newly diagnosed myeloma patients not eligible for autologous stem cell transplantation: a randomized phase III trial	Sperimentale con farmaco	III	No Profit	Fondazione EMN Italy Onlus
INT 0021/19	A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib	Sperimentale con farmaco	III	Profit	DECIPHERA PHARMACEUTICALS, LLC
INT 0023/19	A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity	Sperimentale con farmaco	II	No Profit	SARC
INT 0025/19	A phase 2, single arm, European multi-center trial evaluating the efficacy of afatinib as first-line or later-line treatment in advanced chordoma.	Sperimentale con farmaco	II	No Profit	Leiden University Medical Centre
INT 0030/19	A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)	Sperimentale con farmaco	III	Profit	MSD Italia Srl
INT 0047/19	ERibulin in Advanced Solitary fibrous tumor, an ItaliaN sarcoma Group phase II study (ERASING)	Sperimentale con farmaco	II	No Profit	Italian Sarcoma Group (I.S.G.)
INT 0068/19	A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TRIal with Ribociclib [LEE011]: NATALEE)	Sperimentale con farmaco	III	Profit	Novartis Farma S.p.A.
INT 0072/19	A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)	Sperimentale con farmaco	III	Profit	Incyte Corporation
INT 0088/19	A Phase II, Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib (The SAVANNAH Study)	Sperimentale con farmaco	II	Profit	AstraZeneca S.p.A.
INT 0092/19	A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin forNeoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patientswith Muscle-Invasive Bladder Cancer	Sperimentale con farmaco	III	Profit	AstraZeneca S.p.A.
INT 0093/19	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-Eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0094/19	A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)	Sperimentale con farmaco	III	Profit	MSD Italia Srl
INT 0095/19	MALIBU trial - Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas	Sperimentale con farmaco	II	No Profit	IELSG (INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP)
INT 0124/19	A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors	Sperimentale con farmaco	I/II	Profit	Loxo Oncology Incorporate
INT 0139/19	A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MED14736) as preoperative treatment in rectal cancer	Sperimentale con farmaco	II	No Profit	Azienda Unità Sanitaria Locale della Romagna
INT 0142/19	A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0143/19	Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients	Sperimentale con farmaco	II	No Profit	IFOM - Fondazione Istituto FIRC di Oncologia Molecolare
INT 0164/19	An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments	Sperimentale con farmaco	I	Profit	Novartis Farma S.p.A.
INT 0167/19	A phase I/II, open-label, dose-escalation and expansion study of entrectinib (RXDX-101) in pediatrics with locally advanced or metastatic solid or primary CNS tumors and/or who have no satisfactory treatment options	Sperimentale con farmaco	I/II	Profit	F. Hoffmann-La Roche, Ltd
INT 0170/19	Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CheckMate 76K: CHECKpoint pathway and nivolumAb clinical Trial Evaluation 76K)	Sperimentale con farmaco	III	Profit	Bristol-Myers Squibb S.r.l.

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0174/19	A Phase III, Randomised, international trial comparing mFOLFIRINOX triplet chemotherapy to mFOLFOX for highrisk stage III colon cancer in adjuvant setting	Sperimentale con farmaco	III	No Profit	UNICANCER
INT 0176/19	Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)	Sperimentale con farmaco	II	Profit	GlaxoSmithKline S.p.A.
INT 0177/19	Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC)	Sperimentale con farmaco	II	No Profit	EORTC (European Organisation for Research and Treatment Cancer)
INT 0192/19	Targeting triple negative BREAst cancer metabolism with a combination of chemotherapy and a diet mimicking FASTING plus/minus metformin in the preoperative setting: the BREAKFAST trial	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0198/19	A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma	Sperimentale con farmaco	III	Profit	AstraZeneca S.p.A.
INT 0241/19	A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo Plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer (RUBY)	Sperimentale con farmaco	III	Profit	TESARO Inc.
INT 0243/19	This is a multicenter, stratified, randomized, open-label comparator-controlled, Phase III study in patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs, diagnosed within 6 months prior to screening, comparing treatment with Lutathera (7.4GBq/200 mCi x 4 administrations every 8± 1 weeks; cumulative dose: 29.6 GBq/800mCi) plus octreotide long-acting (30 mg every 8 weeks during Lutathera treatment and every 4 weeks after last Lutathera treatment) and high dose octreotide long-acting (60 mg every 4 weeks).	Sperimentale con farmaco	III	Profit	Advanced Accelerator Applications SA
INT 0013/20	A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (Pvd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma	Sperimentale con farmaco	III	Profit	Janssen-Cilag International NV
INT 0018/20	A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor	Sperimentale con farmaco	I/II	Profit	DECIPHERA PHARMACEUTICALS, LLC
INT 0033/20	AN OPEN-LABEL, MULTI-CENTER, PHASE IB/II STUDY OF GLOFITAMAB AND ATEZOLIZUMAB OR POLATUZUMAB VEDOTIN (PLUS A SINGLE PRE-TREATMENT DOSE OF OBINUTUZUMAB) IN ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL NONHODGKIN'S LYMPHOMA	Sperimentale con farmaco	I/II	Profit	Roche S.p.A.
INT 0035/20	A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0043/20	Assessment of bone response after LHRH-A and Enzalutamide plus minus Zoledronic Acid in prostate cancer patients with hormone sensitive metastatic bone disease: a prospective, phase II, randomized, multicenter study".	Sperimentale con farmaco	II	No Profit	A.S.S.T. degli Spedali Civili di Brescia
INT 0070/20	A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)	Sperimentale con farmaco	I/II	Profit	Loxo Oncology Incorporate
INT 0074/20	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0184/20	A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE18 / ENGOT-cx11)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0200/20	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLUB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLUB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER	Sperimentale con farmaco	III	Profit	F. Hoffmann-La Roche, Ltd
INT 0202/20	A Phase 1/2, multicenter, open-label study to assess safety, pharmacokinetics, and preliminary efficacy of CC-220, alone and in combination with an anti-CD20 monoclonal antibody (mAb) in subjects with relapsed or refractory lymphomas	Sperimentale con farmaco	I/II	Profit	Celgene Corporation
INT 0204/20	Randomized phase II study of PAnitumumab REchallenge followed by REgorafenib versus the reverse sequence in RAS and BRAF WILD-TYPE chemorefractory metastatic colorectal cancer patients	Sperimentale con farmaco	II	No Profit	Gruppo Oncologico del Nord Ovest (G.O.N.O.)
INT 0207/20	A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer	Sperimentale con farmaco	III	Profit	Karyopharm Therapeutics, Inc.
INT 0228/20	A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02B	Sperimentale con farmaco	I/II	Profit	MSD Italia Srl
INT 0232/20	A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).	Sperimentale con farmaco	III	Profit	ITM Solucin GmbH
INT 0259/20	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB or IV Non-Small Cell Lung Cancer.	Sperimentale con farmaco	III	Profit	GlaxoSmithKline Research & Development Ltd

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0262/20	A phase II randomized non-comparative study, with neoadjuvant plus adjuvant therapy with combination or sequence of vemurafenib, cobimetinib, and atezolizumab in patients with high-risk, surgically resectable BRAF mutated and wild-type Melanoma	Sperimentale con farmaco	II	No Profit	Fondazione Melanoma Onlus
INT 0263/20	A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Sperimentale con farmaco	III	Profit	Janssen-Cilag International NV
INT 0267/20	An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGFTargeted Therapies	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0284/20	A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma	Sperimentale con farmaco	I/II	Profit	Janssen-Cilag International NV
INT 0291/20	A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)	Sperimentale con farmaco	III	Profit	Merck KGaA
INT 0293/20	Tremellumab aNd durvalumab combination For the non-operative management (NOM) of Microsatellite Instability (MSI)-high resectable gastric or gastroesophageal Junction cancer: The multicentre, single-arm, multi-cohort, Phase II INFINITY study.	Sperimentale con farmaco	II	No Profit	Gruppo Oncologico del Nord Ovest (G.O.N.O.)
INT 0005/21	A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)	Sperimentale con farmaco	III	Profit	Janssen-Cilag International NV
INT 0008/21	A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 /ENGOT-en11 / GOG-3053)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0035/21	An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK- 7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy	Sperimentale con farmaco	III	Profit	MSD Italia Srl
INT 0055/21	An open-label, multicenter, phase I study evaluating the safety and pharmacokinetics of escalating doses of RO7428751 in participants with relapsed or refractory multiple myeloma	Sperimentale con farmaco	I	Profit	F. Hoffmann-La Roche, Ltd
INT 0056/21	A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation	Sperimentale con farmaco	I/II	Profit	Novartis Farma S.p.A.
INT 0059/21	BRIDGE trial: Phase II trial of durvalumaB and chemotheRapy Induction followed by Durvalumab and radiotherapy in larGe volumE stage III NSCLC	Sperimentale con farmaco	II	No Profit	IRCCS Istituto di Ricerche Farmacologiche Mario Negri
INT 0060/21	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0096/21	Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial). A randomized, multidisciplinary, multinational AIO/DGAV/DGVS phase III trial.	Sperimentale con farmaco	III	No Profit	University Medical Center Hamburg-Eppendorf
INT 0103/21	An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as Firstline Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme S.p.A
INT 0104/21	A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Sperimentale con farmaco	III	Profit	Janssen-Cilag SpA
INT 0124/21	A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxetecan in Subjects with HER2 Positive Metastatic and/or Unresectable Gastric or Gastro Esophageal Junction (GEJ) Adenocarcinoma Subjects who have Progressed on or After a Trastuzumab- Containing Regimen (DESTINY-Gastric04)	Sperimentale con farmaco	III	Profit	DAICHI SANKIO DEVELOPMENT LIMITED
INT 0125/21	A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)	Sperimentale con farmaco	III	Profit	Incyte Corporation
INT 0127/21	A phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of adjuvant atezolizumab or placebo and trastuzumab emtansine for her2-positive breast cancer at high risk of recurrence following preoperative therapy	Sperimentale con farmaco	III	Profit	F. Hoffmann-La Roche, Ltd
INT 0128/21	A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Coformulated quavonlimab (MK-1308)/pembrolizumab) Versus Other Treatments in Participants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)	Sperimentale con farmaco	II	Profit	Merck Sharp & Dohme Corporation
INT 0149/21	A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0153/21	A Randomized, Open-Label Phase 2/3 Study comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in participants with Advanced Nonsmall Cell Lung Cancer who have progressed on prior Anti-PD-(L)1 Therapy and Chemotherapy (Costar Lung)	Sperimentale con farmaco	II/III	Profit	GlaxoSmithKline Research & Development Ltd
INT 0154/21	A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)	Sperimentale con farmaco	II	Profit	Merck Sharp & Dohme Corporation

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0155/21	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma	Sperimentale con farmaco	III	Profit	Incyte Corporation
INT 0156/21	The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Sperimentale con farmaco	III	Profit	Adlai Nortye USA Inc.
INT 0176/21	ShorTrip study - Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoadjuvant therapy for locally advanced rectal cancer	Sperimentale con farmaco	II	No Profit	Fondazione GONO
INT 0194/21	A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma	Sperimentale con farmaco	III	Profit	Bristol-Myers Squibb International Corporation
INT 0202/21	A phase 1/2 study exploring the safety and activity of Trifluridine/tipiracil in combination with capecitabine and bevacizumab in metastatic colorectal cancer patients.	Sperimentale con farmaco	I/II	No Profit	Fondazione GONO
INT 0228/21	A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimsetinib to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor (MOTION)	Sperimentale con farmaco	III	Profit	DECIPHERA PHARMACEUTICALS, LLC
INT 0239/21	A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE896 / ENGOT-ov65)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0241/21	An open-label, Phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in combination with pembrolizumab in participants with advanced solid tumors	Sperimentale con farmaco	I	Profit	Bayer AG
INT 0268/21	Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer	Sperimentale con farmaco	II	No Profit	Fondazione GONO
INT 0020/22	A Phase 2 study of PHE885, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma	Sperimentale con farmaco	II	Profit	Novartis Pharma AG
INT 0022/22	A Phase 2/3 Study of ALX148 in Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma	Sperimentale con farmaco	II/III	Profit	ALX ONCOLOGY
INT 0023/22	A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive- Stage Small Cell Lung Cancer	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0039/22	A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0066/22	RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors	Sperimentale con farmaco	II/III	Profit	Ayala Pharmaceuticals, Inc
INT 0067/22	An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)	Sperimentale con farmaco	II	Profit	Incyte Corporation
INT 0095/22	A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma	Sperimentale con farmaco	III	Profit	ADVENCHEN LABORATORIES, LLC
INT 0118/22	A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3)	Sperimentale con farmaco	III	Profit	AstraZeneca AB
INT 0133/22	A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy	Sperimentale con farmaco	III	Profit	Janssen-Cilag International NV
INT 0135/22	A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06A	Sperimentale con farmaco	I/II	Profit	Merck Sharp & Dohme Corporation
INT 0137/22	A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients	Sperimentale con farmaco	II	No Profit	GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE
INT 0156/22	A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)	Sperimentale con farmaco	I/III	Profit	AMGEN INC.
INT 0161/22	A Phase 3, Randomized, Open-label (Sponsor Blinded) Study of Relatlimabnivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer	Sperimentale con farmaco	III	Profit	Bristol-Myers Squibb International Corporation
INT 0216/22	A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme S.p.A
INT 0005/23	A First-in-Human, Open-label, Dose-escalation Trial with Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects with Malignant Solid Tumors	Sperimentale con farmaco	I/II	Profit	Genmab A/S
INT 0021/23	A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatineligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0023/23	An open label, first-in-human study of BAY 2927088 in participants with advanced nonsmall cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation	Sperimentale con farmaco	I	Profit	Bayer AG
INT 0024/23	A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer	Sperimentale con farmaco	II	Profit	GlaxoSmithKline Research & Development Ltd

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0025/23	CAPRI 2 GOIM study: investigate the efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line.	Sperimentale con farmaco	II	No Profit	GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE
INT 0041/23	CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer	Sperimentale con farmaco	III	Profit	Eli Lilly & Company, Lilly Corporate Center
INT 0043/23	(Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors	Sperimentale con farmaco	III	Profit	Cogent Biosciences
INT 0055/23	A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD- (L)1 Therapy and Platinum-based Chemotherapy: LATIFY	Sperimentale con farmaco	III	Profit	AstraZeneca AB
INT 0058/23	A randomized, double-blind, placebo-controlled, Phase 2 study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with nonsquamous non-small cell lung cancer who have progressed on immunotherapy.	Sperimentale con farmaco	II	Profit	iTeos Belgium SA
INT 0071/23	A PHASE III, DOUBLE-BLIND, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) VERSUS PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE BLADDER CANCER WHO ARE CTDNA POSITIVE FOLLOWING CYSTECTOMY	Sperimentale con farmaco	III	Profit	F. Hoffmann-La Roche, Ltd
INT 0108/23	Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation	Sperimentale con farmaco	I/II	Profit	Zhejiang GenFleet Therapeutics Co., Ltd.
INT 0111/23	A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma	Sperimentale con farmaco	III	Profit	Bristol-Myers Squibb S.r.l.
INT 0115/23	An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma	Sperimentale con farmaco	III	Profit	SERVIER AFFAIRES MÉDICALES
INT 0116/23	A randomized, open-label, phase 2 study of Botensilimab (AGEN1181) as monotherapy and in combination with Balstilimab (AGEN2034) or investigator's choice standard of care (Regorafenib or Trifluridine and Tipiracil) for the treatment of refractory metastatic colorectal cancer	Sperimentale con farmaco	II	Profit	Agenus, Inc.
INT 0161/23	A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma	Sperimentale con farmaco	III	Profit	MSD Italia Srl
INT 0168/23	A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor	Sperimentale con farmaco	III	Profit	Abbisko Therapeutics Co., Ltd.
INT 0182/23	A phase III, multicenter, randomized, open-label study comparing the efficacy and safety of Glofitamab (RO7082859) in combination with Polatuzumab Vedotin plus Rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus Pola-R-CHP in previously untreated patients with large B-cell lymphoma	Sperimentale con farmaco	III	Profit	F. Hoffmann-La Roche, Ltd
INT 0184/23	A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tiselimab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Sperimentale con farmaco	II	Profit	BEIGENE USA, INC
INT 0199/23	A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors	Sperimentale con farmaco	II	Profit	Merck Sharp & Dohme Corporation
INT 0222/23	A phase 2, open-label, multicenter, rollover study to provide continued treatment for participants previously enrolled in studies of pascalisib (INC050465)	Sperimentale con farmaco	II	Profit	Incyte Corporation
INT 0249/23	A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFRmutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment	Sperimentale con farmaco	III	Profit	Summit Therapeutics
INT 0046/09	A phase 3, multicentre, randomized, controlled study to determine the efficacy and safety of cyclophosphamide, lenalidomide and dexamethasone (CRD) versus melphalan (200 mg/m2) followed by stem cell transplant in newly diagnosed multiple myeloma subjects	Sperimentale con farmaco	III	No Profit	FO.NE.SA Onlus
INT 0066/10	Localized high-risk soft tissue sarcomas of the extremities and trunk wall in adults: an integrating approach comprising standard vs histotype-tailored neoadjuvant chemotherapy	Sperimentale con farmaco	II	No Profit	Italian Sarcoma Group (I.S.G.)
INT 0042/11	SUTNET Trial: biological and clinical phase II study of sunitinib in patients with unresectable and/or metastatic pheochromocytomas/paragangliomas	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0089/11	A randomized phase III study to compare Bortezomib, melphalan, prednisone (VMP) with high dose melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myeloma	Sperimentale con farmaco	III	No Profit	HOVON FOUNDATION/GIMEMA
INT 0066/12	A phase III multicenter, randomized study comparing consolidation with 90YTTRIUM-LABELED IBRITUMOMAB TIUXETAN (ZEVALIN®) radioimmunotherapy vs autologous stem cell transplantation (ASCT) in patients with relapsed/refractory follicular lymphoma (FL) aged 18-65 years	Sperimentale con farmaco	III	No Profit	Fondazione Italiana Linfomi (FIL)
INT 0031/13	A multicenter, open label study of weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in newly diagnosed Multiple Myeloma (MM) patients	Sperimentale con farmaco	I/II	No Profit	STICHTING EUROPEAN MYELOMA NETWORK (EMN)
INT 0055/13	A randomized, multicenter, open-label phase III study to evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy for patients with HER2-positive primary breast cancer who have residual tumor present pathologically in the breast or axillary lymph nodes following preoperative therapy	Sperimentale con farmaco	III	Profit	Roche S.p.A.
INT 0094/13	A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab Versus Ipilimumab Monotherapy in Subjects with Previously Untreated Unresectable or Metastatic Melanoma	Sperimentale con farmaco	III	Profit	Bristol-Myers Squibb S.r.l.
INT 0170/13	A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors	Sperimentale con farmaco	I/II	Profit	Bristol-Myers Squibb S.r.l.

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0029/14	PERTuzumab-trastuzumab plus IETrozole In endocrine Sensitive breast cancer: a phase II neoAdjuvant study – PER ELISA	Sperimentale con farmaco	II	No Profit	AS.T.R.O (Association for Translation research in Oncology)
INT 0045/14	Activity and safety of Everolimus in combination with Octreotide LAR and Metformin in patients with advanced pancreatic well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, open, monocentric, prospective study	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0074/14	A phase II study of Chlorambucil in combination with subcutaneous Rituximab followed by maintenance therapy with subcutaneous Rituximab in patients with extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT LYMPHOMA)	Sperimentale con farmaco	II	No Profit	Fondazione Italiana Linfomi (FIL)
INT 0147/14	A phase III, multicentre, randomized, controlled study to determine the efficacy and safety of standard schedule versus a new algorithm of dose reductions in elderly and unfit newly diagnosed multiple myeloma patients receiving lenalidomide plus steroids	Sperimentale con farmaco	III	No Profit	FO.NE.SA (Fondazione Neoplasie Sangue Onlus)
INT 0015/15	A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs)	Sperimentale con farmaco	II	No Profit	EORTC NOCI - Head & Neck Groups
INT 0019/15	Randomized, multicenter, phase III, open-label study of alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer	Sperimentale con farmaco	III	Profit	F. Hoffmann-La Roche, Ltd
INT 0031/15	A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIB/C or Stage IV Melanoma in Subjects who are at High Risk for Recurrence	Sperimentale con farmaco	III	Profit	Bristol-Myers Squibb International Corporation
INT 0094/15	Phase 2 open label randomized study of radiotherapy, concomitant nimotuzumab and vinorelbine and re-irradiation at relapse versus radiotherapy and multiple elective radiotherapy courses with concomitant vinorelbine and nimotuzumab for newly diagnosed childhood and adolescence diffuse intrinsic pontine glioma (dipg)	Sperimentale con farmaco	III	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0110/15	Phase II study on Regorafenib in advanced Solitary Fibrous Tumor	Sperimentale con farmaco	III	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0173/15	Pomalidomide combined with Carfilizomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethasone vs Pomalidomide maintenance for patients with Multiple Myeloma in progression after prior 1st line treatment with Lenalidomide and Bortezomib	Sperimentale con farmaco	II	No Profit	DUTCH-BELGIAN COOPERATIVE TRIAL GROUP FOR HEMATOLOGY - HOVON
INT 0081/16	A Phase II single-arm trial to investigate tepotinib in advanced (locally advanced or metastatic) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION)	Sperimentale con farmaco	II	Profit	Merck KGaA
INT 0103/16	Assessment of Ramucirumab plus paclitaxel as switch MAINTenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III Trial	Sperimentale con farmaco	III	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0119/16	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	Sperimentale con farmaco	III	Profit	TESARO Inc.
INT 0136/16	A randomized open-label phase 3 trial comparing bevacizumab + erlotinib vs erlotinib alone as first line treatment of patients with EGFR mutated advanced non squamous non small cell lung cancer	Sperimentale con farmaco	III	No Profit	Istituto Naz. Tumori IRCCS "Fondazione Pascale" (NA)
INT 0137/16	A phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma	Sperimentale con farmaco	II	No Profit	Istituto Naz. Tumori IRCCS "Fondazione Pascale" (NA)
INT 0143/16	Phase II Study of Neoadjuvant Chemotherapy With Dose-Dense Paclitaxel in Association With Carboplatin followed by Radical Surgery for Locally Advanced Cervical Cancer (FIGO stage IB2- IIIA) Patients	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0164/16	A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients with metastatic melanoma and BRAF mutation	Sperimentale con farmaco	II	No Profit	Fondazione Melanoma Onlus
INT 0165/16	Phase II trial of sunitinib in patients with type B3 thymoma or thymic carcinoma in second and further lines (Style trial)	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0179/16	A phase III, doubleblinded, randomized, placebo-controlled study of atezolizumab plus cobimetinib and vemurafenib versus placebo plus cobimetinib and vemurafenib in previously untreated BRAFV600 mutation-positive patients with metastatic or unresectable locally advanced melanoma	Sperimentale con farmaco	III	Profit	F. Hoffmann-La Roche, Ltd
INT 0182/16	A phase 3, multinational, randomized, open-label, parallel-arm study of Avelumab (MSB0010718C) in combination with Axitinib (Inlyta®) versus Sunitinib (Sutent®) monotherapy in the first-line treatment of patients with advanced renal cell carcinoma	Sperimentale con farmaco	III	Profit	Pfizer Inc.
INT 0021/17	A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies	Sperimentale con farmaco	I/II	Profit	Novartis Farma S.p.A.
INT 0067/17	Solitary fibrous tumor: phase II study on TRabectedin versus Adriamycin plus DACarbazine in advanced patients	Sperimentale con farmaco	II	No Profit	Italian Sarcoma Group (I.S.G.)
INT 0148/17	A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination .	Sperimentale con farmaco	II	No Profit	Policlinico Universitario Gemelli (RM)
INT 0150/17	Advanced or Metastatic Collecting ducts renal cell carcinoma	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0178/17	Phase II study to test Pembrolizumab (MK-3475) in first line treatment of advanced NSCLC patients with PD-L1 low tumors (<50%)_ PEOPLE TRIAL (Pembrolizumab in Pd-L1 low Expressors)	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0190/17	A Phase 2, Open-Label, 2- Cohort Study of INCB050465, a PI3Kd Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor.	Sperimentale con farmaco	II	Profit	Incyte Corporation
INT 0194/17	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR)	Sperimentale con farmaco	III	Profit	EISAI Limited
INT 0016/18	Phase II multicentre trial of perioperative chemotherapy in operable patients with gastric cancer (PERISCOPE trial)	Sperimentale con farmaco	II	No Profit	Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
INT 0023/18	Improving treatment strategies in thymic epithelial tumors: a TYME collaborative effort	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0036/18	Adjuvant capecitabine in high risk pseudomyxoma peritonei patients treated with cytoreductive surgery (crs) and hyperthermic intraperitoneal chemotherapy (HIPEC)	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0045/18	Exploiting metformin plus/minus cyclic Fasting Mimicking Diet (FMD) to improve the efficacy of first line chemo-immunotherapy in advanced LKB1-inactive lung adenocarcinoma	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0055/18	Phase III, multicenter, randomized, double-blind, placebo-controlled study of atezolizumab (Anti-PD-L1 antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck	Sperimentale con farmaco	III	Profit	F. Hoffmann-La Roche, Ltd
INT 0057/18	A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kd Inhibitor, in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)	Sperimentale con farmaco	II	Profit	Incyte Corporation
INT 0060/18	A phase III, doubleblinded, multicenter, randomized study evaluating the efficacy and safety of neoadjuvant treatment with atezolizumab or placebo in combination with platinum-based chemotherapy in patients with resectable stage II, IIIa, or select IIIB non-small cell lung cancer	Sperimentale con farmaco	III	Profit	F. Hoffmann-La Roche, Ltd
INT 0079/18	Immunotherapy Followed By EGFR Inhibitor In Locally Advanced Or Metastatic Squamous Cell Cancer Of The Skin: Tackling Primary And Secondary Resistance	Sperimentale con farmaco	II	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0087/18	A Multicenter, Open-label, Randomized, Phase III Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with Advanced Endometrial Cancer	Sperimentale con farmaco	III	Profit	EISAI Limited
INT 0138/18	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)	Sperimentale con farmaco	III	Profit	MSD Italia Srl
INT 0177/18	A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer	Sperimentale con farmaco	III	Profit	AstraZeneca AB
INT 0203/18	Randomised, double-blind, placebo-controlled study of the, efficacy, safety and tolerability of EPA-FFA gastro-resistant capsules, in patients with familial adenomatous polyposis (FAP)	Sperimentale con farmaco	III	Profit	S.L.A. PHARMA
INT 0212/18	A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants	Sperimentale con farmaco	II	Profit	GlaxoSmithKline S.p.A.
INT 0001/19	A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma	Sperimentale con farmaco	II	Profit	Incyte Corporation
INT 0002/19	A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (OPC)	Sperimentale con farmaco	II	Profit	ISA Therapeutics B.V.
INT 0020/19	Phase Ib, open-label, multicenter study of oral LXH254- centric combinations in adult patients with advanced or metastatic KRAS or BRAF mutant non-small cell lung cancer or NRAS mutant melanoma	Sperimentale con farmaco	I	Profit	Novartis Farma S.p.A.
INT 0089/19	A Phase 1/2, open-label, multi-center study of the safety and efficacy of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies	Sperimentale con farmaco	I/II	Profit	Kymab Limited
INT 0119/19	A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma	Sperimentale con farmaco	III	No Profit	European Thoracic Oncology Platform (ETOP)
INT 0141/19	A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)	Sperimentale con farmaco	I/II	Profit	Celgene Corporation
INT 0144/19	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)	Sperimentale con farmaco	III	Profit	SpringWorks Therapeutics
INT 0169/19	A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients with Selected Advanced/Metastatic Solid Tumors	Sperimentale con farmaco	I	Profit	Nerviano Medical Sciences S.r.l.
INT 0171/19	Phase 2, open-label, single-arm trial of trastuzumab deruxtecan (ds-8201a) in HER2 positive, unresectable or metastatic gastric or gastroesophageal junction (gej) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen	Sperimentale con farmaco	II	Profit	DAICHI SANKIO DEVELOPMENT LIMITED
INT 0217/19	A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor	Sperimentale con farmaco	I/II	Profit	Eli Lilly & Company, Lilly Corporate Center
INT 0237/19	Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic Non-Squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors	Sperimentale con farmaco	III	Profit	Sanofi-Aventis S.p.A.
INT 0239/19	PHASE II STUDY OF AVELUMAB AND CETUXIMAB AND MODIFIED FOLFFOXIRI AS INITIAL THERAPY FOR RAS WILD-TYPE UNRESECTABLE METASTATIC COLORECTAL CANCER PATIENTS	Sperimentale con farmaco	II	No Profit	Gruppo Oncologico del Nord Ovest (G.O.N.O.)
INT 0242/19	Phase 2 randomized trial of trabectedin + olaparib vs. trabectedin in advanced,metastatic or unresectable soft tissue sarcoma after failure of standard treatments	Sperimentale con farmaco	II	No Profit	Italian Sarcoma Group (I.S.G.)
INT 0015/20	A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected population of participants with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)(LEAP-010)	Sperimentale con farmaco	III	Profit	Merck Sharp & Dohme Corporation
INT 0016/20	A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions.	Sperimentale con farmaco	II	Profit	Janssen-Cilag International NV
INT 0108/20	A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations	Sperimentale con farmaco	III	Profit	TAKEDA Pharmaceuticals
INT 0111/20	Phase II study on TSR-042 in advanced clear cells sarcoma	Sperimentale con farmaco	II	No Profit	Italian Sarcoma Group (I.S.G.)
INT 0180/20	Phase I/II study on safety and efficacy of NMS-01940153E in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy	Sperimentale con farmaco	I/II	Profit	Nerviano Medical Sciences S.r.l.
INT 0182/20	A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer	Sperimentale con farmaco	III	Profit	F. Hoffmann-La Roche, Ltd

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0201/20	A safety Run-in and phase 2, open-label, multicentre, study investigating safety, tolerability and effectiveness of Venetoclax add in combination at Fludarabine, Cytarabine and Idarubicine in induction therapy of new onset non-m3 acute myeloid leukemia	Sperimentale con farmaco	I/II	No Profit	Fondazione GIMEMA Onlus
INT 0203/20	Phase II Study on Nivolumab in combination with FOLFIRI/Bevacizumab in first line chemotherapy of Advanced COloRectal cancer RASm/BRAFm patients	Sperimentale con farmaco	II	No Profit	Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
INT 0209/20	Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).	Sperimentale con farmaco	II	No Profit	CONSORZIO ONCOTECH
INT 0234/20	A phase IIIB, single arm, multicenter s tudy of Atezolizumab (Tecentriq) in combination with Bevacizumab to investigate safety and efficacy in patients with unresectable hepatocellular carcinoma not previously treated with systemic therapy - AMETHISTA	Sperimentale con farmaco	III	Profit	Roche S.p.A.
INT 0002/21	A phase Ia/Ib, open-label, multicenter, global, dose-escalation study to evaluate the safety and pharmacokinetics of Xmab24306 as a single agent and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors	Sperimentale con farmaco	I	Profit	Genentech Inc.
INT 0037/21	A PHASE II CLINICAL STUDY, ON TRABECTEDIN IN COMBINATION WITH PPARg AGONIST PIGLITAZONE IN PATIENTS WITH ROUND CELL MYXOID LIPOSARCOMAS OR DEDIFFERENTIATED G1 OR G2 LIPOSARCOMAS WITH STABLE DISEASE IN TREATMENT WITH TRABECTEDIN ALONE.	Sperimentale con farmaco	II	No Profit	IRCCS Istituto di Ricerche Farmacologiche Mario Negri
INT 0057/21	A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of nvestigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D	Sperimentale con farmaco	I/II	Profit	Merck Sharp & Dohme Corporation
INT 0061/21	A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers	Sperimentale con farmaco	I/III	Profit	Bristol-Myers Squibb International Corporation
INT 0094/21	A Phase 1b/2a Basket Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Combination Therapy With the Anti-CD19 Monoclonal Antibody Tafasitamab and the PI3K delta Inhibitor Parsaclisib in Adult Participants With Relapsed/Refractory Non- Hodgkin Lymphoma or Chronic Lymphocytic Leukemia (topMIND)	Sperimentale con farmaco	I/II	Profit	Incyte Corporation
INT 0099/21	A randomized, phase 2, double-blind study to evaluate the efficacy of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy in metastatic Non-Squamous Non-Small Cell Lung Cancer	Sperimentale con farmaco	II	Profit	GlaxoSmithKline S.p.A.
INT 0102/21	Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab	Sperimentale con farmaco	II	Profit	Bristol-Myers Squibb S.r.l.
INT 0123/21	A randomized, open-label, multi-arm, two-part, phase II study to assess the efficacy and safety of multiple LXH254 combinations in patients with previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma	Sperimentale con farmaco	II	Profit	Novartis Farma S.p.A.
INT 0148/21	A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Subjects with HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)	Sperimentale con farmaco	II	Profit	Daichi Sankyo Inc.
INT 0175/21	A Phase 2 non-randomized, open-label, multi-cohort, multi center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants with lung cancer or pleural mesothelioma	Sperimentale con farmaco	II	Profit	SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
INT 0197/21	A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation	Sperimentale con farmaco	III	Profit	MIRATI THERAPEUTICS INCORPORATED
INT 0203/21	A multicenter, open-label phase II trial of a new customized dosing (rational adjustment of dose to reduce adverse reactions "RADAR" dosing) of NIRAPARIB as maintenance therapy in platinum sensitive ovarian, fallopian tube or primary peritoneal recurrent cancer patients.	Sperimentale con farmaco	II	No Profit	IRCCS Istituto di Ricerche Farmacologiche Mario Negri
INT 0222/21	A Phase I/Ib, open-label, multi-center study of DFF332 as a single agent and in combination with Everolimus or IO agents in patients with advanced/relapsed ccRCC and other malignancies with HIF2alpha stabilizing mutations.	Sperimentale con farmaco	I	Profit	Novartis Farma S.p.A.
INT 0225/21	A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nabpaclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)	Sperimentale con farmaco	III	Profit	Novartis Farma S.p.A.
INT 0263/21	daNIS-3: An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC)	Sperimentale con farmaco	II	Profit	Novartis Pharma AG
INT 0266/21	PICCOLO: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum- Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression	Sperimentale con farmaco	II	Profit	Immunogen Inc
INT 0269/21	A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling	Sperimentale con farmaco	I/II	Profit	Blueprint Medicines Corporation
INT 0038/22	A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation	Sperimentale con farmaco	III	Profit	AMGEN INC.
INT 0061/22	Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Sperimentale con farmaco	I/II	Profit	Apollomics Inc.
INT 0062/22	A Phase I, open-label, dose escalation study of oral LGK974 in patients with malignancies dependent on Wnt ligands	Sperimentale con farmaco	I	Profit	Novartis Pharma AG
INT 0068/22	A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer	Sperimentale con farmaco	II	Profit	Merck Sharp & Dohme Corporation
INT 0093/22	Open-label, Phase 2 study, evaluating the efficacy and safety of tusamitamab ravtansine in non-squamous non-small-cell lung cancer (NSQ NSCLC) participants with negative or moderate CEACAM5 expression tumors and high circulating CEA	Sperimentale con farmaco	II	Profit	Sanofi-Aventis Recherche e Developpement
INT 0116/22	Adjuvant encorafenib & binimetinib vs. placebo in fully resected stage IIB/C BRAF V600E/K mutated melanoma: a randomized triple-blind phase III study in collaboration with the EORTC Melanoma Group	Sperimentale con farmaco	III	Profit	PIERRE FABRE MÉDICAMENT

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0117/22	A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS > and =1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.	Sperimentale con farmaco	II	Profit	Incyte Biosciences International
INT 0122/22	Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer	Sperimentale con farmaco	III	Profit	Exelixis, Inc
INT 0151/22	Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors	Sperimentale con farmaco	I/II	Profit	BEIGENE USA, INC
INT 0165/22	A phase 2/3 study to evaluate the efficacy and safety of unesbulin in unresectable or metastatic, relapsed or refractory leiomyosarcoma	Sperimentale con farmaco	II/III	Profit	PTC THERAPEUTICS INC.
INT 0166/22	A phase I/Ib, open-label, multi-center, study of QEO278 in patients with advanced solid tumors	Sperimentale con farmaco	I/II	Profit	Novartis Pharma AG
INT 0175/22	A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected squamous cell carcinoma of the head and neck, who are at high risk for relapse and are ineligible for high-dose cisplatin	Sperimentale con farmaco	III	Profit	Merck KGaA
INT 0205/22	A Phase I study to evaluate the safety and dosimetry of 68Ga-labelled OncoFAP derivatives in patients with solid tumors	Sperimentale con farmaco	I	Profit	Philogen S.p.A.
INT 0026/23	A randomised, open-label, Phase II, dose/schedule optimisation study of NUC-3373/leucovorin/irinotecan plus bevacizumab (NUFIRI-bev) versus 5-FU/leucovorin/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients with previously treated unresectable metastatic colorectal cancer	Sperimentale con farmaco	II	Profit	NuCan plc
INT 0059/23	A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer	Sperimentale con farmaco	I/II	Profit	Janssen-Cilag International NV
INT 0185/23	A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors	Sperimentale con farmaco	I/II	Profit	Bristol-Myers Squibb S.r.l.
INT 0078/24	A monocentric randomized study of Yttrium90 Radioembolization with or without balloon microcatheter	Sperimentale con dispositivo	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0112/24	Xpert Bladder Monitor: a Non-Invasive Follow-Up Tool for Detecting Relapse in High Grade or High Risk Bladder Cancer	Sperimentale con dispositivo	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0126/24	OncoSil Pancreatic cancer post-marketing clinical Registry	Sperimentale con dispositivo	Non applicabile	Profit	OncoSil Medical Ltd
INT 0109/12	SHARE - Cyberknife Partial Breast Irradiation for Early Stage Breast Cancer. A phase I prospective study	Sperimentale con dispositivo	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0244/21	Randomized, double-blind, placebo-controlled clinical trial to evaluate safety and efficacy of Jalosome® Soothing gel in the prevention and treatment of radiation-induced dermatitis in patients with head and neck cancer	Sperimentale con dispositivo	Non applicabile	Profit	Welcare Research srl
INT 0123/22	An Interventional, Multicentric, Explorative, Randomized, Evaluator-blinded, Pre-Marketing Study to Evaluate Performance and Safety of GERDOFF® for the prevention of Radiation-Induced Oral Mucositis in patients receiving radiotherapy for head and neck cancer	Sperimentale con dispositivo	Non applicabile	Profit	SOFAR S.p.A.
INT 0066/05	Registry of congenital malformations in Lombardy	Registro	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0105/12	The Lombardy Rare Donor Programme	Registro	Non applicabile	No Profit	A.O. Ospedale Niguarda Ca' Granda (MI)
INT 0133/12	Chronic Lymphocytic Leukemia (CLL) Registry: a prospective, observational study within the Rete Ematologica Lombarda	Registro	Non applicabile	No Profit	A.O. Ospedale Niguarda Ca' Granda (MI)
INT 0139/14	Italian peripheral neuroblastic tumors Registry (RINB) - AIEOP (Italian Association of Pediatric Hematology Oncology) Registry	Registro	Non applicabile	No Profit	Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)
INT 0175/14	Identification of potential targets for therapy and expression of immune inhibitors in the neoplastic stroma in patients with neuroblastoma	Registro	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0051/15	Italian Registry of minimally invasive liver resections within the IGoMILS Association (Italian Group of Minimally Invasive Liver Surgery)	Registro	Non applicabile	No Profit	Italian Group of Minimally Invasive Liver Surgery I Go MILS
INT 0084/15	Peritoneal Surface Oncology Group International (PSOGI) Registry on Peritoneal Mesothelioma	Registro	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0153/15	DIPG Registry and Imaging Repository	Registro	Non applicabile	No Profit	Dutch Children Oncology Group (DCOG)
INT 0201/16	RETroperitoneal Sarcoma Registry (RESAR):prospective collection of primary retroperitoneal sarcoma patient's data, radiological and pathological material for the TransAtlantic Retroperitoneal Sarcoma Working Group	Registro	Non applicabile	No Profit	Transatlantic Retroperitoneal Sarcoma Working Group (TARPSWG)
INT 0012/18	Register Hereditary Tumors Digestive System	Registro	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0070/18	Prospective, Multicenter, Study on the Clinical Outcome of Thyroid Carcinoma Patients	Registro	Non applicabile	No Profit	Università La Sapienza (Roma)
INT 0297/20	A "PHYSICIAN & PATIENT-POWERED" COHORT REGISTRY – MY MYELOMA	Registro	Non applicabile	No Profit	Fondazione EMN Italy Onlus
INT 0068/21	International registry for patients with a paediatric relapsed or refractory hepatoblastoma or hepatocellular carcinoma - RELIVE	Registro	Non applicabile	No Profit	Geneva University Hospital (HUG)
INT 0228/19	Retrospective observational study on the safety of Nivolumab in patients with metastatic renal cell carcinoma and renal failure	Osservazionale retrospettivo su farmaco	Non applicabile	No Profit	Azienda USL-IRCCS di Reggio Emilia
INT 0081/20	A multicenter retrospective study on clinical characteristics to predict the time to next treatment (progression free survival) in chronic lymphocytic leukemia patients during the era of new drugs	Osservazionale retrospettivo su farmaco	Non applicabile	No Profit	Università Cattolica del Sacro Cuore - Policlinico Gemelli
INT 0175/20	Osteonecrosis of the jaw in metastatic renal cell carcinoma patients with bone metastases. A retrospective multicentric trial (REBONE trial)	Osservazionale retrospettivo su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0035/23	Combo immunotherapy efficacy and tolerability in melanoma patients with brain metastases: an outcome research study of IMI group: COMBO IMMUNO IMI	Osservazionale retrospettivo su farmaco	Non applicabile	No Profit	A.O.Universitaria di Perugia
INT 0080/23	Niraparib First Line EAP in Ovarian Cancer: An observational retrospective real life study with a prospective follow up period	Osservazionale retrospettivo su farmaco	Non applicabile	No Profit	Istituto Naz. Tumori IRCCS "Fondazione Pascale" (NA)
INT 0086/23	Decisional role of interim PET in relapsed/refractory classical Hodgkin lymphoma treated with BEGEV chemotherapy as first salvage	Osservazionale retrospettivo su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0237/23	Valutazione retrospettiva multicentrica di fattori predittivi per lo sviluppo di cardiopatia in pazienti affetti da Linfoma Diffuso a grandi cellule (DLBCL) sottoposti a chemioterapia con antracicline.	Osservazionale retrospettivo su farmaco	Non applicabile	No Profit	IRCCS Istituto Tumori Giovanni Paolo II Bari
INT 0289/23	First-line treatment with Brentuximab-vedotin plus AVD chemotherapy for patients affected by classical Hodgkin Lymphoma in a real-life cohort: predictive value of PET2, efficacy and safety	Osservazionale retrospettivo su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0084/24	A National Retrospective Observational Study Characterizing Utilization and Effectiveness Outcomes in Patients with Metastatic Breast Cancer Receiving Abemaciclib	Osservazionale retrospettivo su farmaco	Non applicabile	Profit	Eli Lilly Italia S.p.A.
INT 0104/24	International multicenter retrospective study of Pleomorphic Rhabdomyosarcoma (PRMS) and Spindle cell/ sclerosing Rhabdomyosarcoma (S-RMS), a push platform study	Osservazionale retrospettivo su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0031/18	Clinical impact of somatostatin analogs (SSA) in combination to peptide receptor radionuclide therapy (PRRT) versus PRRT alone in advanced well-differentiated neuroendocrine tumour patients	Osservazionale retrospettivo su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0138/20	Predictive impact of Peripheral blood parameters on clinical outcome during CDK 4/6 inhibitors treatment in patients with Advanced hormone Receptor-positive HER2-negative breast cancer : the retrospective, multicenter Italian PALMARES study	Osservazionale retrospettivo su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0139/22	A MULTI-COUNTRY OBSERVATIONAL RETROSPECTIVE STUDY TO EVALUATE THE PREVALENCE OF PD-L1 AND ITS ROLE IN PATIENTS WITH TNBC TREATED WITH SYSTEMIC THERAPY (VANESSA)	Osservazionale retrospettivo su farmaco	Non applicabile	Profit	F. Hoffmann-La Roche, Ltd
INT 0186/22	Retrospective observational study in patients with relapsed / refractory primary mediastinal lymphoma treated with pembrolizumab or nivolumab in combination with brentuximab vedotin in a real-life context	Osservazionale retrospettivo su farmaco	Non applicabile	No Profit	Policlinico Sant'Orsola Malpighi - Bologna (BO)
INT 0139/23	A Real Life on the effects of long term bone targeting agents administration beyond 24 months in metastatic breast cancer	Osservazionale retrospettivo su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0140/23	A retrospective observational study of anti resorptive therapy in patients with bone metastases due to prostate cancer effectiveness on pain control and skeletal related events in real life	Osservazionale retrospettivo su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0144/23	An observational study on (Follicular) dendritic, Accessory, and Histiocytic Neoplasm", FASHION study	Osservazionale retrospettivo su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0151/23	Study to evaluate the extended overall survival (OS) from parrisal trial: efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with HER2 negative, ER+ metastatic breast cancer.	Osservazionale retrospettivo su farmaco	Non applicabile	Profit	MedSir Medica Scientia Innovation Research
INT 0236/23	Salvage Treatment with Glofitamab in patients affected by relapsed/refractory Non Hodgkin B cell lymphoma: a Gimema-Fil study	Osservazionale retrospettivo su farmaco	Non applicabile	No Profit	Fondazione GIMEMA Onlus
INT 0184/14	Project Plan Movember GAP3 Active Surveillance	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Erasmus University Medical Center - Rotterdam (NL)
INT 0134/17	Adolescents and young adults with cancer in Italy. How to ensure access to the best care and quality of survival (Survivors Cohort)	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0184/18	Genomic test aiming to identify actionable mutations in Hormone Receptor (HR) negative/Her2 positive or triple negative (TN) breast cancer resistant to neoadjuvant therapy: Feasibility and improvement	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Ospedale Policlinico San Martino - IRCCS per l'Oncologia
INT 0192/18	Urothelial tumors of the high urinary tract and bladder in subjects with or without Lynch syndrome	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0135/19	The role of micrometastasis and isolated tumor cells (ITCs) in uterine cancers (endometrial/cervical) submitted to sentinel lymph nodes (SLN) procedure: an observational study	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0154/19	Number-Dose in TARE: impact of the number of microspheres per unit activity and of voxel dosimetry radiobiological parameters on treatment planning and on clinical outcome in radioembolization of hepatocellular carcinoma	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0190/19	Analisi retrospettiva comparativa degli esiti a breve e lungo termine dei pazienti affetti da poliposi sottoposti ad intervento chirurgico con tecnica open versus tecnica laparoscopica	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0020/20	Integrating pharmacogenomic and pharmacometabolomic data towards personalized opioid therapies for cancer pain	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Istituto di Tecnologie Biomediche – Consiglio Nazionale delle Ricerche
INT 0057/20	Reversion of resistance to mTOR inhibitors with the addition of exemestane in patients with malignant	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0084/20	Analysis of clinical-pathological features and response to treatments in an international cohort of patients affected by NUTM1-rearranged carcinomas: a multicentric retrospective observational study	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0095/20	Role of cytoreductive surgery in advanced endometrial cancer. Multicenter retrospective study	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	IRCCS "Fondazione Pascale" (NA)
INT 0130/20	Identification of molecular predictors of response to PRRT in patients with GEP-NETS	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	A.O. Ospedale Policlinico Consorziale Bari
INT 0140/20	Assessing the role of various treatment modalities for endometrial cancer patients: a retrospective and prospective evaluation	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0165/20	Study of DNA repair genes mutations and tumor biomarkers for better breast cancer risk estimates and treatment options	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	IFOM - Fondazione Istituto FIRCC di Oncologia Molecolare
INT 0196/20	A Master Protocol Empowering Mechanobiology Translational Research in Breast Cancer (METAMECH)"	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	IFOM - Fondazione Istituto FIRCC di Oncologia Molecolare
INT 0245/20	A master protocol empowering Precision Research in Colorectal Cancer (ALFAOMEGA)	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	IFOM - Fondazione Istituto FIRCC di Oncologia Molecolare
INT 0023/21	Targeting of proteasome-associated and non-associated deubiquitinases to overcome drug resistance of ovarian carcinoma.	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0040/21	Development and validation of multiparametric radiomic models in breast cancer: characterization of the breast parenchyma and prediction of the tumor molecular profile	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Istituto Nazionale Tumori IRCCS - Fondazione Pascale Napoli
INT 0075/21	Retrospective analysis of salivary gland adenoid cystic carcinoma patients treated with carbon ion radiotherapy	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0083/21	pPredicting cardiovascular diseases in adolescent and young breast cancer patients (ROSANNA)	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0113/21	DNA repair alterations as prognostic/predictive biomarkers in biliarypancreatic cancers	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0134/21	Validation of Predictive Knowledge Based Models as Decision Support for Quality Control: A Multicenter Cooperative Effort to Improve the Quality and Consistency of Pediatric CNS Radiotherapy	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Istituto Oncologico Veneto (IOV)
INT 0164/21	Italian Registry on rare genito-urinary neoplasms Meet-URO 23 study	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Istituto Oncologico Veneto (IOV)
INT 0229/21	Molecular Characterization of Melanoma in Adolescents and Young Adults	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0233/21	A retrospective and prospective clinical study on high-complex and rare tumors of the thorax, abdomen and soft tissue.	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Policlinico Sant'Orsola Malpighi - Bologna (BO)
INT 0252/21	Retrospective and prospective observational study in pediatric patients with rare cancer	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)
INT 0253/21	Molecular characterization of Synovial Sarcomas in adolescents and young adults	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0033/22	Interaction between cancer cells and adipocytes in triple negative breast cancer patients	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0051/22	Lung function toxicity after irradiation and or chemotherapy for brain tumors	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0052/22	PROGNOSTIC AND PREDICTIVE RELEVANCE OF HIGH GRADE NEN CLASSIFICATIONS – ROLE OF MORPHOLOGY, IMMUNOPHENOTYPE AND MOLECULAR FEATURES	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Beaujon-Bichat Hospitals APHP / University of Paris
INT 0105/22	Evaluation of cost-effectiveness of robotic surgery, compared to the thoracoscopic and open surgery, in lung resections lesions based on "real world" efficacy and cost data from ATS in Milan	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	ATS Milano Città Metropolitana
INT 0110/22	Partial Breast Irradiation: long term outcomes of patients with a median follow up of two years	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0126/22	Key-Early: A Study to describe the diagnostic and therapeutic path of patients with NSCLC in Early Stage and locally advanced	Osservazionale retrospettivo non su farmaco	Non applicabile	Profit	MSD Italia Srl
INT 0141/22	Optimized selection and clinical outcomes of advanced pancreatic cancer patients treated in phase I clinical trials: a multicentric, observational study	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0171/22	Male Breast Carcinoma: a Multicentric Analyses on Radiation Therapy Outcomes	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0202/22	Beyond BMI: external exposure, dysbiosis and systemic inflammation in the development of overweight – related chronic diseases in women	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0215/22	Application of proteomics to evaluate disease aetiology and predict outcomes in patients with soft tissue sarcoma.	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	ProCan Laboratory
INT 0011/23	Patient Outcomes following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer: A GO SOAR led Study (GO SOAR2)	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Global Gynaecological Oncology Surgical Outcomes Collaborative
INT 0013/23	Systemic treatment in intra-abdominal desmoid tumor: a single-institution retrospective observational case-series analyses.	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0016/23	Deciphering the Exposome by Metabolomic Technology in Breast Cancer	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Medical University Vienna
INT 0031/23	Surgical management of the duodenum during multivisceral resection for primary retroperitoneal sarcoma	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0036/23	Improving the success rate for thoracic radiotherapy through specific cardiac substructure dosimetry: location matters – retrospective study.	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0074/23	Algorithm proposal of molecular profiling (MP), in salivary gland cancers (SGCS) patients, through the retrospective observational analysis of patients that performed a next-generation sequencing (NGS) analysis: a monocentric NGS-SGC Study.	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0075/23	Retrospective single-center observational study to evaluate prognosis and treatment of patients with early stage breast cancer with stage T1mic/T1a/T1b/T1cN0/mi: MINIT	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0078/23	Multilayer biological characterization of advanced follicular lymphoma: a translational study from FIL_FOLL12 trial	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione Italiana Linfomi (FIL)
INT 0098/23	Assessment of the prognostic impact of the published European Society of Gynecologic Oncology quality indicators for advanced ovarian cancer surgery - Founding project of The ESGO Database based on The ESGO Consortium of Accredited Centers	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	ESGO (European Society of Gynaecological Oncology)
INT 0135/23	Innovative immunotherapies for renal cell carcinoma (ImmunHUB)	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0150/23	A retrospective observational study on the Longitudinal plasma Epstein-Barr Virus (EBV) DNA Assessment in non-endemic EBV-related nasopharyngeal cancer patients treated with curative intent and subsequent clinical-instrumental follow-up. The LEA Study.	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0152/23	A monocentric observational-retrospective study aimed at evaluating the impact of molecular tests and precision oncological therapies on the outcome of patients with advanced thyroid cancers, and directed to define a molecular profiling algorithm. The OrientHyring Study.	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0153/23	Prognostic role of immune infiltrate in pancreatic ductal adenocarcinoma (PDAC). How quality and quantity of immune cells in the tumor microenvironment influence the prognosis of patients affected by PDAC	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0156/23	Tumour-to-germline approach for the identification of carriers of germline variants in predisposing genes among patients affected with a tumour in childhood/young adulthood	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0179/23	Discovery of predictive biomarkers of response and/or resistance to atezolizumab + bevacizumab in advanced HCC: an international, multicenter study	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Icahn School Of Medicine At Mount Sinai
INT 0262/23	Immunological profile of pediatric patients with osteosarcoma: looking for new prognostic/predictive factors?	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0290/23	Observational study for HPV - associated cervix diseases	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0008/24	The application of artificial intelligence in assessing intra-abdominal desmoid tumors in familial adenomatous polyposis patients	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0083/24	A step towards Inclusive medicine: implementation Of gender-Related indicators (PANDORA)	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0159/24	A Comprehensive Multicenter Retrospective Study on Neoadjuvant Chemotherapy in Intrahepatic Cholangiocarcinoma Treatment	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	University Health Network
INT 0021/16	Observational Retrospective Study on Prognostic Relevance of NENs classification at the light of recent literature evidences concerning morphology, immunophenotype and molecular features with focus on Role of Immunologic Factors in NENs prognosis	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0171/16	Observational Study on Prognostic and Predictive role of Immunocontexture and Microenvironment characterization in Non Small Cell Lung Carcinomas	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0012/17	Role of mast cell infiltration in breast carcinoma and correlation with tumor outcome	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0029/18	Clinicopathological study of endometrial stromal sarcoma, high grade with –BCOR rearrangement	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0030/18	Impact of Everolimus-induced precocious modifications of systemic Metabolism on the prognosis of postmenopausal women with advanced hormone receptor-positive HER2 negative breast cancer: The retrospective, multicenter Italian EVERMET study	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0074/18	Identification of a miRNA based predictor of risk of relapse for epithelial ovarian cancer: towards a clinical-grade assay	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0061/19	Radical Abdominal Hysterectomy vs Laparoscopic Radical Hysterectomy in cervical cancer stage IA1-IB1: Does tumor size matter? A Multicenter Cohort study	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Grupo Area Unidades Quirúrgica
INT 0113/19	Retrospective observational study on the predictive and prognostic role of inflammatory biomarkers in patients with metastatic renal carcinoma treated with Nivoluma	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Ospedale Policlinico San Martino - IRCCS per l'Oncologia
INT 0176/20	A Study on the factors that influence colonoscopic surveillance in Lynch syndrome patients	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Warwick University
INT 0047/21	Analysis of events involved in the progression/relapse in Wilms tumor	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0083/22	Molecular profiling of papillary thyroid carcinomas in patients previously treated with radiation therapy and/or chemotherapy for a pediatric cancer	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Università di Catania
INT 0015/23	Dissecting mechanisms of stromal invasion by spatially resolved whole transcriptome analysis in microinvasive breast cancer	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0029/23	An observational-retrospective study of patients with basal cell carcinoma treated with Vismodigib, according to clinical practice, who achieved complete disease remission. The VISMO-BCC Study.	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0283/23	Early recurrent primary retroperitoneal sarcomas (RPS) have similar survival to non-operated primary RPS: was surgery worthy?	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0057/17	Risk of colorectal cancer and clinical features in patients with associated diagnosis of Lynch Syndrome and inflammatory bowel diseases. A Retrospective Study	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0130/18	Collection of clinical, pathological and biomolecular data of patients with colorectal cancer and inclusion in international biobanks for research purposes	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	BBMRI-ERIC
INT 0010/19	Harnessing osteosarcoma stem cell/mesenchymal features to enhance treatment susceptibility	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0222/19	Development and validation of a nomogram predictive of overall and progression-free survival in patients with oropharyngeal cancer in a south-European setting: NETWORK OPC	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	A.S.S.T. degli Spedali Civili di Brescia
INT 0049/20	Frequency of subsolid lesions in asymptomatic subjects undergoing lung screening with low-dose chest CT and its correlation with inflammatory and respiratory profile	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0114/20	COVID-19 infection in multiple myeloma patients: an european observational study	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione EMN Italy Onlus
INT 0217/20	Identification of gene expression profile associated with favorable prognosis in patients undergoing radical surgery for pancreatic adenocarcinoma	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0220/20	FDG-PET evaluation for marginal zone lymphoma and its prognostic role: an international multicenter retrospective analysis (PIMENTO)	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	IELSG (INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP)
INT 0257/20	Cancer and COVID-19	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0304/20	Tumor and circulating biomarkers and their correlation with outcomes after priming with temozolomide and treatment with temozolomide, nivolumab and ipilimumab at low doses in patients treated within the institutional non-profit MAYA study	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0118/21	Identification of cancer-related biomarkers in plasma to improve surveillance in Lynch Syndrome individuals	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0180/21	Analisi dei fattori clinicopatologici nei pazienti con melanoma cutaneo di stadio IIA per identificare più accuratamente i gruppi a maggiore e minore rischio di progressione di malattia	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0208/21	HPD-1st line. Hyperprogressive disease upon first line immunecheckpoint blockade in advanced NSCLC patients	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0009/22	LA-HN Italy: A Study to describe the diagnostic and therapeutic scenario of patients with Locally Advanced HNSCC in Italy	Osservazionale retrospettivo non su farmaco	Non applicabile	Profit	MSD Italia Srl
INT 0012/23	Radiomic Analysis of Liver Metastases in Patients with Colo-Rectal Cancer Undergoing Surgery	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	IFO-IRE Istituto Nazionale Tumori Regina Elena Roma
INT 0093/23	Identifying the existential needs of hospice patients and their caregivers	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0095/23	Clinical features, treatment and outcome of patients with Retroperitoneum Primary Germ Cell Tumor	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0132/23	Inguinal Sarcomas - a retrospective analysis of diagnosis, clinical features, treatment patterns and outcomes (I-Sarc): a study by TARPSWG.	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fox Chase Cancer Center
INT 0174/23	High-risk medulloblastoma, a retrospective study of institutional case series	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0175/23	High-grade osteosarcoma of the craniofacial district in pediatric age: review of a referral center's case history and literature with attention to new therapeutic perspectives.	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0291/23	Reproducibility in PD-L1 interpretation and scoring in melanoma tissue samples: A multicentre study of the Italian Melanoma Intergroup (IMI)	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Università degli Studi di Firenze
INT 0003/24	The Italian OHDSI network for clinical research using healthcare Real World Data: a feasibility study	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Università degli Studi di Pavia (UNIPV)
INT 0032/24	CNS sarcomas with CIC alterations: meta analysis of molecular and clinical data and development of new treatment strategies	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Hopp Children's Cancer Centre at the NCT Heidelberg (KITZ)
INT 0048/24	DIGIST project (Deep learning on histology in GIST: from the proof-of-concept to clinical applicability)	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0077/24	Impact of anti PD-1 therapy in children, adolescents and young adults (CAYA) melanoma patients	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Università degli Studi - Perugia
INT 0113/24	Incidence, prevalence, and characterisation of medicines with suggested drug shortages in Europe	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Università di Oxford
INT 0207/24	Diagnosis of Malignant Peripheral Nerve Sheath Tumors: A Pathological Review of Italian Patients	Osservazionale retrospettivo non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0046/07	Prostate cancer research international: active surveillance (PRIAS)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Erasmus University Medical Center - Rotterdam (NL)
INT 0028/11	Rabdomiosarcoma of adults. An observational prospective study	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	ISG e RTR
INT 0068/12	Rare tumors in gynecologic oncology: retrospective and prospective collection data on diagnosis and treatment of rare gynecologic neoplasia	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	A.O. Ospedale Policlinico Consorziale Bari
INT 0114/13	Patients with atypical osteosarcoma and/or are not eligible in other ISG clinical trials	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Italian Sarcoma Group (I.S.G.)
INT 0103/14	Observational retrospective and prospective study on patients enrolled in AIEOP and IPINET Centers	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)
INT 0140/14	Prospective study registry of peripheral neuroblastic tumours patients presenting with spinal canal involvement (SCI)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)
INT 0022/15	Observational study to assess the prognostic impact of factors related to the immune response in non-small cell lung cancer	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0117/15	Explorative Evaluation of new potential prognostic factor in patient with gastrointestinal cancer	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0135/16	Endometrial stromal tumors: an observational study	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Italian Sarcoma Group (I.S.G.)
INT 0173/16	Long-term comorbidities among survivors of adult Hodgkin's lymphoma	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0073/17	Epithelioid sarcoma. An observational study	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Italian Sarcoma Group (I.S.G.)
INT 0160/17	Development, pilot testing and face validity of a neuropsychomotor observation/evaluation grid for pediatric patients affected by CNS neoplasia in order to personalize the rehabilitation path during adjuvants oncological treatments	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0168/17	Prospective Europe-Wide Study of Duodenal Disease in MUTYH-Associated Adenomatous Polyposis (MAP)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Università di Cardiff

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0182/17	Non-invasive molecular monitoring of minimal residual disease to predict outcome and progression free survival in PET-avid lymphomas	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0183/17	ITCC PEDIATRIC PRECLINICAL POC PLATFORM (ITCC-P4)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Alleanza Contro il Cancro
INT 0206/17	Observational, multicenter, retrospective and prospective study on patients with Langerhans cell histiocytosis	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)
INT 0220/17	ASPEN STUDY - Asymptomatic Small Pancreatic Endocrine Neoplasms - ASPEN Study	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Ospedale San Raffaele IRCCS
INT 0064/18	Precision immunotherapy for cancer treatment: understanding resistance to therapy, improving patients selection, and designing novel therapeutic strategies	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Azienda Ospedaliera Universitaria Senese, Siena
INT 0067/18	Observational study (retrospective and prospective) to evaluate prognostic and predictive biomarkers in malignant pleural mesotelioma	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0071/18	Prospective translational study investigating predictors of outcome in metastatic renal cell carcinoma patients treated with Nivolumab (I-Rene trial)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0076/18	Studio PINK – Prevention, Imaging, Network, Knowledge	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Consiglio Nazionale delle Ricerche - ISTITUTO DI FISIOLOGIA CLINICA IFC-CNR PISA
INT 0077/18	Integration of radiomics, genomics and immunoprofiling into predictive and prognostic models in soft tissue sarcoma patients (SARCOMICS study).	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0090/18	Immunological profiling of patients with desmoid-type fibromatosis under wait and see approach	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0132/18	Umbrella Protocol SIOP (Société Internationale d'Oncologie Pédiatrique) - Renal Tumour Study Group 2016	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)
INT 0147/18	Identification of prognostic and predictive biomarkers of response or resistance to treatments in patients with metastatic renal cell carcinoma (mRCC): a translational, prospective trial	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0150/18	Development and characterization of preclinical models of pediatric sarcoma for studying new drugs and new therapeutic combinations	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0168/18	VIP: Validation of the Italian version of the Patient-Reported Outcomes - Common Terminology Criteria for Adverse Events (PRO-CTCAE): A Prospective Multicenter Observational Study on different cancer types	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Federation of Italian Cooperative Groups
INT 0170/18	Epigenetic modeling/remodeling of cancer metastases and tumor immune contexture to improve efficacy of immunotherapy	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Azienda Ospedaliera Universitaria Senese, Siena
INT 0171/18	An international phase IV field study for the reliability and validity of the EORTC Thyroid Cancer Module THY34	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Mainz University Hospital
INT 0205/18	National registry of Actionable mutations	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Associazione Italiana di Oncologia Medica (AIOM)
INT 0034/19	A Prospective Observational Multicenter cohort study on Psychological and Emotional Distress in Patients receiving Allogeneic Stem Cells Transplantation	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	GITMO (Gruppo Italiano per il trapianto di Midollo Osseo)
INT 0054/19	Redefining the "risk" of cancer relapse by serum metabolomic and ctDNA in patients with early stage colon cancer	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	USL Toscana Centro
INT 0056/19	Characterization of antitumor activity mediated by leukocytes redirected on tumor by new generation antibodies	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0103/19	Generation of experimental models from precancerous/cancerous lesions in subjects with familial adenomatous polyposis (FAP)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0127/19	AntiGEnicity vs. Immunosuppression in Colorectal cancer (ANGELICO)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0130/19	Observational study, for Quality Assessment, of Sarcoma as a model to improve diagnosis and clinical care of rare tumors through a European and Latin American multidisciplinary NETWORK (SELNET)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Grupo Español de Investigación en Sarcomas (GEIS)
INT 0136/19	A master protocol empowering Precision Research in Colorectal Cancer	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	IFOM - Fondazione Istituto FIRC di Oncologia Molecolare
INT 0149/19	Retrospective/Prospective review for outcomes evaluation in patients affected by primary or recurrent colo-rectal cancer at the National Cancer Institute of Milan	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0184/19	Multicenter, prospective, observational study on microbiome in children with neuroblastoma: role in aetiology, response to treatment and prognosis	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	IRCCS "Giannina Gaslini"
INT 0200/19	Neuropathic Cancer Pain Assessment: Application and accuracy of the new EAPC/IASP algorithm	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0244/19	Patient-derived Organoids to optimize personalized medicine in colon and rectal cancer (POSEIDON)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0249/19	Patient-derived Organoids to optimize personalized medicine in rare peritoneal surface malignancies (POSEIDON II)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0009/20	Italian Vats Lobectomy Registry	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0010/20	Prospective study on elderly (= 65 years) patients affected with classical Hodgkin Lymphoma undergoing Comprehensive Geriatric Assessment at diagnosis	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione Italiana Linfomi (FIL)
INT 0052/20	A retrospective study evaluating prognostic factor for recurrent HPV-related genital dysplasia	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0061/20	Profiling immune responses in healthy donors to improve the knowledge of cancer-related immune dysfunctions	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0067/20	Serological surveillance with rapid testing of SARS-CoV-2 in healthcare personnel of the Hematology and Oncology divisions at the National Cancer Institute of Milano	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0103/20	SARS-CoV-2 infection in patients with hematological malignancies: the Italian Hematology Alliance.	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi
INT 0174/20	A prospective international observational study on Epithelioid Haemangiioendothelioma 1/describing the clinical presentation, natural history, and treatment outcomes, 2/evaluating cytokines and hormones as biomarkers and 3/generating patient-derived preclinical models as a tool to assess the activity of anticancer agents and validate novel therapeutic targets	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0193/20	Mechanistic computational modelling of radiation damage to microvasculature and of its effect on tumour microenvironment	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0244/20	Preparation and titration of fluorescent extracellular vesicles for in-vivo imaging of G.I. cancers	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0272/20	Financial Toxicity and Patient-Reported Outcomes in Italian Patients affected by Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Ospedale San Raffaele IRCCS
INT 0274/20	Study of the immune-related marker expression in extracellular vesicles (EV) from plasma of cancer patients as a non-invasive tool to monitor systemic immunity in clinical setting	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0280/20	Evaluation of Cardiotoxicity and Hypertension in Patients With Non-Metastatic Castration Resistant Prostatic Carcinoma (Apo-CARDIO1)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Ospedale "A. Tortora", Pagani (SA)
INT 0299/20	InterNational Registry on SARS-CoV-2 positive Neuroendocrine neoplasm patients	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Istituto Europeo di Oncologia

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0012/21	Collecting Ducts Carcinoma: in depth exploration and biologically driven therapy (CICERONE)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0043/21	Registry of the European reference network on Rare Adult Solid Cancer "EURACAN"	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0046/21	Determining Post-Operative Morbidity & Mortality Following Gynaecological Oncology Surgery: a Multicentre, International, Prospective Cohort Study Led by the Global Gynaecological Oncology Surgical Outcomes Collaborative (GO SOAR)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Global Gynaecological Oncology Surgical Outcomes Collaborative
INT 0048/21	Quantifying systemic immunosuppression to personalize cancer therapy - SERPENTINE	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0053/21	Investigating pseudomyxoma peritonei: building a European multicentre cohort to accelerate new therapeutic perspectives (VOLTRON)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0069/21	Study of peripheral blood immunological and transcriptional profiles in osteosarcoma pediatric patients	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0071/21	Prospective and retrospective observational study for the discovery of novel biomarkers in patients with melanoma undergoing systemic anti-cancer therapy	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0076/21	Interrogating circulating lung tumor cells to guide personalized therapies and identify novel targets to hit metastasis initiating cells	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0089/21	Knowledge At the Tip of Your fingers: Clinical Knowledge for Humanity	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0106/21	Observational Study on treatment of skeletal Ewing sarcoma at diagnosis (ISG-EWoss study)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Italian Sarcoma Group (I.S.G.)
INT 0107/21	Observational Study on treatment of skeletal Ewing sarcoma at diagnosis (ISG-EWoss study)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Italian Sarcoma Group (I.S.G.)
INT 0131/21	Prospective observational multicenter study on the role of body mass index (BMI) in the development of thrombotic complications in cancer patients with PICC	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Neurologico Carlo Besta (MI)
INT 0139/21	Retrospective and prospective analysis about risk factors and outcome of the oncoematological patients admitted to the Italian Pediatric Intensive Care Units: a multicentric study.	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Azienda Ospedaliera di Padova
INT 0140/21	ItalyLynch: mainstreaming the diagnosis of Lynch Syndrome	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione GISCAD
INT 0204/21	Observational multicentric Study in Localized Osteosarcoma AIEOP/ISGOS2 Oss	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Italian Sarcoma Group (I.S.G.)
INT 0212/21	Observational multicentric Study in Localized Osteosarcoma AIEOP/ISGOS2 Oss	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Italian Sarcoma Group (I.S.G.)
INT 0216/21	Prospective observational study investigating the role of liquid biopsy and patients-derived organoids (PDOs) as novel tools for assessing tumor biology and acquired drug resistance in patients with tumors of the gastrointestinal and biliary-pancreatic tract, neuroendocrine tumors and Merkel cell carcinomas.	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0220/21	Retrospective and Prospective Observational Monocentric Study with Biological Samples on the effect on the mRNA splicing of variants of uncertain significance in the gastrointestinal cancers predisposition genes with the aim to define personalized surveillance and risk reduction measures in a greater number of subjects potentially at risk	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0231/21	Observational study on the clinical and anatomopathological characteristics and outcomes of patients suffering from gastrointestinal and neuroendocrine cancers treated at National Cancer Institute of Milan	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0274/21	Non-invasive identification of relapse /non-response to conservative treatment in patients with high-grade bladder cancer at high risk of relapse	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0278/21	No-profit, national observational study on patients with solid tumors characterized by next generation sequencing (NGS) and discussed within the Molecular Tumor Board	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0283/21	Validation of the analytical validity of comprehensive genomic profiling on ctDNA for liquid biopsy implementation in precision oncology	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0017/22	AIOCC Italian Registry on Head and Neck Carcinoma AIR Study	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Associazione Italiana Oncologia Cervico-Cefalica (AIOCC)
INT 0048/22	Genomic profiling for therapeutic purposes in sarcomas and molecular tumor board (MTB): retrospective / prospective study in reference centers	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	IFO-IRE Istituto Nazionale Tumori Regina Elena Roma
INT 0050/22	Siblings after oncological disease in pediatric age	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0056/22	Intraoperative neurophysiologic evaluation of pelvic splanchnic nerves during radical hysterectomy: a way to preserve nerve fibers and their function	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0057/22	You Goody: a web-based prospective study on diet and lifestyles for the prevention of chronic degenerative diseases	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0073/22	Bedside Shift Report: a tool for improving Hematology Nurse accountability and to encourage patient's and caregiver's empowerment The experience of Hematology unit at Istituto Nazionale dei Tumori in Milan	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0098/22	BRCA and Homologous Recombination Deficiency assessment at the bedside: implementation of diagnostic algorithms for tailoring treatment	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0101/22	Retrospective and prospective observational study in patients with advanced basal cell carcinoma	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	SiDeMaST, Società Italiana di Dermatologia Medica, Chirurgica e di Malattie Sessualmente Trasmesse,
INT 0108/22	Non-interventional, multicenter, prospective, cohort study assessing the quality of life and hormonal levels in premenopausal patients with hormone receptor-positive and HER-2-negative Early Breast Cancer in Italy – Rose Study - CLIN-52014-452	Osservazionale prospettico non su farmaco	Non applicabile	Profit	Ipsen S.p.A.
INT 0142/22	Circulating microRNAs for early diagnosis of breast cancer	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0147/22	ISLUNG: Integrative science, Intelligent data platform for Individualized LUNG cancer care with Immunotherapy (Psychological sub-study: prospective)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0172/22	Precision medicine approaches for neoadjuvant therapy in high-risk sarcoma patients	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Institute of Cancer Research /Royal Marsden NHS Trust
INT 0176/22	A PROSPECTIVE OBSERVATIONAL COHORT STUDY TO EVALUATE miRNA 371 AND OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED GERM CELL TUMORS	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo (TO)
INT 0188/22	Transversal prospective observational study for the evaluation of the satisfaction of the elderly patient with respect to the treatment received in the Laser Therapy Unit.	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0197/22	Squamous cell cancers arising from the skin: unraveling the response and resistance upon anti-PD(L)1 agents	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0200/22	Pilot study on the use of iENTER, iCONSENT and iPARTICIPATE e-tools	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0218/22	Clinical evaluation of the role of 371 miRNA in stage II A/B < 3 cm non seminomatous germ cell tumors.	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0219/22	Clinical evaluation of the role of 371 miRNA in stage I small testicular masses.	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0221/22	Global collaboraTION on CIC-DUX4, BCOR-CCN3, high-grade Undifferentiated round cell sarcoma (URCS) project	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Istituto Ortopedico Rizzoli
INT 0128/23	Prediction of fermline BRCA 1/2 genes status from healthy ovaries ultrasound images radiogenomics as an innovative tool to prevent BRCA-related cancers (PROBE II).	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Università Cattolica del Sacro Cuore - Policlinico Gemelli
INT 0130/23	Study on diagnostic delay in adolescent patients treated at AIEOP centers, compared with children	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)
INT 0136/23	SATURNO study: multicenter, prospective, non-interventional Italian registry of Advanced/metastatic Urothelial carcinoma	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Federation of Italian Cooperative Oncology Groups (FICOG)
INT 0149/23	Explorative prospective study on perception of enrolled patients of a clinical trial: the Clinical Research Nurses' role	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0154/23	Rare Cancers in Gynecologic Oncology European Network for Gynaecological Oncological Trial groups (ENGOT) Registry	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Istituto di Ricerche Farmacologiche Mario Negri
INT 0211/23	Analysis of eating habits and bowel function of patients with colic polyposis, subjected to prophylactic surgery	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0216/23	Improving therapeutic efficacy in chest radiotherapy by dosimetry on cardiac substructures: location matters – prospective study.	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0242/23	Complexity And Frailty in Cardiothoracic and vascular Anesthesia (CAfCA)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	SIAARTI (Società Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva)
INT 0281/23	Study on the needs of parents with oncological pathologies and their perception of their children's well-being	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0286/23	Prospective observational Study of localized angiosarcoma of any site: ProStars	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Italian Sarcoma Group (I.S.G.)
INT 0007/24	Urinary tract cancer screening: a single-center prospective pilot study (RISP-VUR)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0010/24	Collection of body fluids, diet and lifestyle information for the identification of risk factors and potential biomarkers in early onset colorectal cancer patients	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0065/24	Analysis of lung microbiota in bronchoalveolar lavage of patients with suspected lung cancer and its potential association with the response to immunotherapy	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0066/24	Analysis of immune-related circulating biomarkers in advanced prostate cancer patients: from mice to men, translational analysis of the PROPACRY study	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0086/24	An ambispective cohort study assessing clinical outcomes of adjuvant targeted and immunotherapy in stage III BRAF V600-mutant cutaneous melanoma	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0090/24	Prospective cohort study on thermal Ablation of malignant liver tumors within the IMAGIO project	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Leiden University Medical Centre
INT 0160/24	Study of the Immune Context in Soft Tissue Sarcomas in Relation to Age: New Potential Clinical Implications	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0169/24	The European Registry of Surgical Resection and Ablation for Liver Metastases from Uveal Melanoma (EUROLIMUM)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0032/03	Prognostic significance of blood concentrations of testosterone and insulin in women with early breast cancer	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0054/07	Identification of Men with a genetic predisposition to Prostate Cancer: Target Screening in BRCA1/2 mutation carriers and controls - the IMPACTstudy	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Institute of Cancer Research /Royal Marsden NHS Trust
INT 0032/09	Epidemiologic studies on environmental risk factors and their interactions with genetic factors of bladder cancer and sarcomas	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Istituto Mario Negri (MI)
INT 0011/11	Breathing analysis by electronic nose for detection of ovarian cancer in general population and in population at risk	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0021/11	BioMILD: a prospective study of efficacy of plasma microRNA as first line test for early diagnosis of lung cancer	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0095/11	Active surveillance "SA INT" in prostate cancer patients with low progression risk	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0008/12	Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Ospedali Riuniti - Bergamo
INT 0176/13	Retrospective and prospective study of late radiation damages after focal radiotherapy for childhood brain tumors	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0067/14	Observational study of gastrointestinal, haematologic and urinary toxicity induced by pelvic irradiation for prostate cancer	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Ospedale San Raffaele IRCCS
INT 0053/15	"GYNADART" Adaptive, MRI- guided brachytherapy in definitive treatment of locally advanced cervical carcinoma, according to the international recommendations: feasibility in daily practice, dosimetric and clinical outcome	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0151/15	Observational study designed to evaluate the prognostic and predictive impact of factors related to immunity in cancer patients treated with immunotherapy	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0022/16	Study of gut microbiota in HER2-positive patients treated with trastuzumab-containing therapy	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0113/16	Active Surveillance in early Prostate cancer following multiparametric magnetic Resonance imaging at Istituto Nazionale Tumori	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0128/16	Monitoring disease response in B-cell malignancies using next generation sequencing of circulating plasma immunoglobulin heavy chain gene rearrangements	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0202/16	Prostate Cancer Outcomes Global Initiative to Compare and Reduce Variation in Localised Prostate Cancer ("PCO-CRV")	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Movember Foundation
INT 0011/17	MICRObiota, inflammatory Environment, clinical and Radiomic features as predictors of Normal tissue response in radiotherapy for prostate and head-and-neck cancer. (MICRO-LEARNER)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0014/17	DUE02 - Erectile and urinary dysfunction - 02 Validation of toxicity predictive models after prostate cancer radiotherapy	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0031/17	Prospective validation and comparison of subjective assessment, the International Ovarian Tumour Analysis (IOTA) ADNEX model, logistic regression model LR2, Simple Rules and the Risk of Malignancy Index (RMI) for discrimination between benign and malignant adnexal masses in the hands of ultrasound examiners with different levels of experience (IOTA7)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	University Hospitals Leuven
INT 0033/17	A prospective observational trial on sentinel lymph node biopsy in patients with early stage cervical cancer	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Central and Eastern European Gynecologic Oncology Group (CEEgOG)
INT 0153/17	Histological classification by mass spectrometry in soft tissue sarcoma patients	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0069/18	Exploiting breath analysis for non-invasive breast cancer early detection	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0210/18	Stromal control of lung cancer seeding through fibroblast reprogramming	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0008/19	Prospective multicenter study for the analysis of genomic profiling of sarcomas in pediatric and young adult patients at diagnosis and/or at relapse/refractoriness of disease	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)
INT 0114/19	Laboratory tools for the classification of variants of unknown significance in breast/ovarian predisposition genes	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0152/19	Incorporating the patient voice in sarcoma research: How can we assess health-related quality of life in this heterogeneous group of patients	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Netherlands Cancer Institute
INT 0220/19	Itanet Database - ENETS Registry: multicentric collection of Gastro-Entero-Pancreatic Neuroendocrine Tumor cases	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	ITANET
INT 0019/20	Patient Reported Outcomes Performance. Clinical outcomes reported by head and neck cancer patients	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Azienda USL-IRCCS di Reggio Emilia
INT 0026/20	Image guided intensity modulated External beam radiochemotherapy and MRI based adaptive BRachytherapy in locally advanced Cervical cancer EMBRACE-II	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Medical University Vienna
INT 0055/20	The prognostic performance of liquid biopsy in peritoneal lavage and plasma of patients with locally advanced gastric cancer (liquid study)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0099/20	International registry on head and neck cancer patients with COVID-19 (HERODOTUS: Head and Neck cancer international COVID-19 collabOration)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Head and Neck Cancer International Group (HNCIG)
INT 0126/20	Analysis of choroidal thickness using optical coherence tomography (OCT) and analysis of retinal capillary perfusion using optical coherence tomography angiography (OCTA) after radiotherapy for uveal melanoma	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0141/20	Urine biomarkers validation project	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Norwich Medical School, University of East Anglia
INT 0220/22	Multimomics approach for patients stratification and novel target identification in metastatic clear cell renal carcinoma	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0073/23	Identification of cancer-related biomarkers in plasma to improve surveillance in Lynch Syndrome individuals: a prospective institutional study	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0106/23	EUonQoL- Validation of the European Oncology Quality of Life Toolkit. A European pilot survey.	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0032/17	Chemoresistance in peripheral T cell lymphomas: from a detailed disease characterization to single cell analysis and liquid biopsy	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0118/17	Guideline application in real world: multi-institutional based survey of adjuvant and first line pancreatic ductal adenocarcinoma treatment in Italy	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Associazione Italiana di Oncologia Medica
INT 0137/19	Proget VBM (Value Based Medicine) applied to breast cancer program	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Istituto Europeo di Oncologia
INT 0201/19	Implementation of a standardized Palliative Care Referral System (PCRS) for cancer patients with advanced disease: impact on patient and caregiver satisfaction with care and use of health care resources. PCRS Implementation.	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0012/20	Evaluation of Lung Tissue Characteristics in Fresh Surgical Specimens	Osservazionale prospettico non su farmaco	Non applicabile	Profit	Ethicon Endo-Surgery, Inc
INT 0046/20	International registry on thoracic cancer patients with COVID-19 TERAVOLT (Thoracic cancer international COVID 19 collaboration)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0270/20	A prospective, multicenter survey of human cytomegalovirus (CMV) and other herpesviruses infections and diseases in allogeneic hematopoietic stem cell transplant (ALLO-HSCT) recipients	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	GITMO (Gruppo Italiano per il trapianto di Midollo Osseo)
INT 0147/21	Survey on cancer risk factors in the Chinese community in Milan: the CHINT study	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0011/22	Salvage therapy for relapsed/refractory aggressive B cell lymphomas after CAR T-cells therapy failure: a retrospective analysis	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0145/22	Actual management of biliary tract cancer: the Italian Cholangiocarcinoma DaTaset	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione GONO
INT 0189/22	Analysis of the needs of patients with oncohematological diseases undergoing treatment by infusion with Car-t Cell and their caregivers. Perspectives for personalized care processes.	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0127/23	Experience of palliative cancer care patients of their unmet needs: a Grounded Theory study (GT)	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0203/23	The empty comic	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0026/24	Caring for those who cannot heal. An exploratory survey of hospice nurses' experience of care	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0057/24	Amplification of the antibody variable domains and their use for the construction of a phage display antibody library	Osservazionale prospettico non su farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0205/17	An observational Italian Multicenter study on molecular mechanisms of resistance to trastuzumab in HER-2 positive gastric or gastroesophageal junction (GEJ) cancers: The AMNESIA study	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0223/17	Observational, retrospective and prospective study of the use of Ruxolitinib in patients with myelofibrosis in Lombardia	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi
INT 0138/19	Observational study on skin toxicity by oncological therapies	Osservazionale prospettico con farmaco	Non applicabile	No Profit	IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
INT 0178/19	Evaluation of quantitative parameters by positron emission tomography/computed tomography (FDG-PET/CT) in patients treated with lymphocytes transduced with chimeric antigen receptor against B cells	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0180/19	A multicenter prospective observational study on Chimeric Antigen Receptor (CAR) T-cell therapy for lymphoma: monitoring feasibility, efficacy, toxicity and biomarkers in a real life setting	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0006/20	Observational study on efficacy and safety of 177-Lu-dotatate (Lutathera) treatment in gastroenteropancreatic neuroendocrine tumors	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0028/20	Prospective observational study of correlation between dosimetric data, efficacy and toxicity of treatment with 177-Lu-DOTATATE (Lutathera®) in patients with diagnosis of gastro-entero-pancreatic neuroendocrine tumours	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0172/20	Immunotherapy in patient populations at higher risk of adverse events	Osservazionale prospettico con farmaco	Non applicabile	No Profit	NICSO - Network Italiano Cure di Supporto in Oncologia
INT 0010/21	EBMT Non-Interventional Post-Authorization Study (PASS) on CAR-T therapies	Osservazionale prospettico con farmaco	Non applicabile	No Profit	EBMT (European Society for Blood and Marrow Transplantation)
INT 0182/21	Observational study on the diagnosis and management of chronic lymphocytic leukemia (CLL) in Italy by Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA)	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Fondazione GIMEMA Onlus
INT 0185/21	UNDERSTAND - Unraveling tumor resistance mechanisms in HR+ aDvanced bReaST cANcer underDergoing CDK4/6 inhibitors therapy	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0282/21	Multicentrico Nazionale sul Linfoma di Hodgkin classico in bambini, adolescenti e giovani: AIEOP-PHL-2021	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)
INT 0054/22	Real-life Use of Cabozantinib in Front-line for Metastatic Renal Cell Carcinoma: a Descriptive analysis from the Italian Experience (CabFRONT)	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0187/22	Testosterone replacement Therapy in hypogonadal male advanced cancer patients: the THOR trial	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0032/23	Disease Registry on Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Skipping Alterations MOMENT (Met on sSmall cell caNcer regisTry)	Osservazionale prospettico con farmaco	Non applicabile	Profit	Merck KGaA
INT 0101/23	Predictive impact of Peripheral blood lymphocytes on clinical outcomes during first-line CDK4/6 inhibitors plus endocrine therapy in patients with Advanced hormone Receptor-positive HER2-negative breast cancer: the retrospective-prospective multicenter Italian PALMARES 2 study	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0181/23	Impact of induction therapy with Dara-VTD on collection of hemopoietic stem cells and engraftment in patients with Multiple myeloma eligible to Autologous transplantation	Osservazionale prospettico con farmaco	Non applicabile	No Profit	A.O. Ospedale Policlinico Consorziale Bari
INT 0218/23	Pemigatinib in previously treated patients with locally advanced unresectable or metastatic cholangiocarcinoma and FGFR2 gene fusions or rearrangements: a Real World study.	Osservazionale prospettico con farmaco	Non applicabile	No Profit	A.O.U. Ospedali Riuniti - Ancona
INT 0232/23	UVEAL MELANOMA IN ADVANCED STAGE HLA A*02:01 POSITIVE: TEBENTAFUSP EXTENDED ACCESS PROGRAM IN ITALY (TEBE-EAP ITA)	Osservazionale prospettico con farmaco		No Profit	Policlinico Universitario Gemelli (RM)
INT 0246/23	A prospective, observational cohort study to evaluate the clinical impact of novel monoclonal antibodies (MAB) in B-cell Non-Hodgkin Lymphoma (NHL) in Italian clinical practice.	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Fondazione Italiana Linfomi (FIL)
INT 0020/24	An Observational Multicenter Study to Evaluate Real World Treatment Outcomes of Durvalumab based Regimens in Hepatobiliary Cancers	Osservazionale prospettico con farmaco	Non applicabile	Profit	AstraZeneca S.p.A.
INT 0043/24	Enfortumab Vedotin for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Chemotherapy and Immunotherapy: A Multicenter, Non-interventional Study in Italy EVIDENCE	Osservazionale prospettico con farmaco	Non applicabile	Profit	Astellas Pharma Europe Ltd
INT 0070/24	Efficacy of Isatuximab-based regimens in Relapsed/Refractory Multiple Myeloma with 1q21+	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Azienda USL di Bologna
INT 0118/24	Gastrointestinal Stromal Tumors associated with Neurofibromatosis type 1: observational study by the National Cancer Institute of Milan	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0129/24	Measure of outcomes in patients with advanced ovarian cancer according to Homologous Recombination status and matched therapies in a real-world scenario. A retrospective and prospective, multicenter, two cohort study.	Osservazionale prospettico con farmaco	Non applicabile	No Profit	CONSORZIO ONCOTECH
INT 0144/24	SARCOpenia and simplified geriatric assessment in lymphoma patients undergoing CAR-T cell therapy: the FIL SAR-CAR project	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Fondazione Italiana Linfomi (FIL)
INT 0187/18	An observational prospective study to evaluate minimal residual disease in chronic lymphocytic leukemia patients treated with Venetoclax ABT199 MRD 2018	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0156/19	Gender Difference in side effects of Immunotherapy: a possible clue to optimize cancer treatment	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0115/20	A non-interventional, multi-national, multi-center post-authorization safety study (PASS) to assess the long-term safety and tolerability of Odomzo® (sonidegib) administered in patients with locally advanced basal cell carcinoma (laBCC): NISSO	Osservazionale prospettico con farmaco	Non applicabile	Profit	Sun Pharmaceutical Industries Europe B.V.
INT 0249/20	Two steps Italian prospective observational study assessing the effectiveness and outcomes associated with Lutathera (177Lu) oxodotreotide treatment in adult subjects with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic-neuroendocrine tumours (GEP-NETs) – REAL-LU	Osservazionale prospettico con farmaco	Non applicabile	Profit	Novartis Farma S.p.A.
INT 0013/21	Retrospective-prospective observational study of Italian patients treated in melanoma adjuvant cohort MAP to evaluate relapse free survival and overall survival – MADAM (Maximizing Adjuvant MAP)	Osservazionale prospettico con farmaco	Non applicabile	Profit	Novartis Farma S.p.A.
INT 0135/21	DAROL: Darolutamide Observational Study in non-metastatic castration resistant prostate cancer patients	Osservazionale prospettico con farmaco	Non applicabile	Profit	Bayer Healthcare AG
INT 0138/21	Observational study of effectiveness and safety of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and anti-HER2 target therapy	Osservazionale prospettico con farmaco	Non applicabile	No Profit	CONSORZIO ONCOTECH
INT 0140/22	Health-Related Quality of Life Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with CAR-T Cell Therapy in Real Life: A Multicenter Prospective Observational Study	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Fondazione GIMEMA Onlus
INT 0222/22	A prospective observational international study of cabozantinib tablets in combination with nivolumab as first-line treatment of advanced renal cell carcinoma in adults	Osservazionale prospettico con farmaco	Non applicabile	Profit	IPSEN INNOVATION
INT 0193/14	REASSURE - Radium-223 alpha Emitter Agent in Safety Study in mCRPC population for long-term Evaluation	Osservazionale prospettico con farmaco	Non applicabile	Profit	Bayer Healthcare AG
INT 0056/16	Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) patients: prospective product registry	Osservazionale prospettico con farmaco	Non applicabile	No Profit	FO.NE.SA (Fondazione Neoplasie Sangue Onlus)
INT 0160/19	ZEBRA-cabozantinib in the elderly with metastatic renal cell carcinoma: observational study	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Istituto Oncologico Veneto (IOV)
INT 0124/20	Niraparib as maintenance treatment in platinum responsive ovarian cancer patients: a real life study by MITO group	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Policlinico Universitario Gemelli (RM)
INT 0255/23	EVA l'impatto degli eventi avversi, prodotti dagli anticorpi coniugati, sulla qualità di vita in pazienti con patologia mammaria metastatica: studio osservazionale multicentrico retrospettivo – prospettico	Osservazionale prospettico con farmaco	Non applicabile	No Profit	IRCCS Centro di Riferimento Oncologico - Aviano (PN)
INT 0261/23	Pazopanib monotherapy in patients with metastatic uterine leiomyosarcoma: real life experience	Osservazionale prospettico con farmaco	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0128/22	APOLLO 11consortium in advanced lung cancer patients treated with innovative therapies: integration of real world data and translational research	Osservazionale con dispositivo	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0083/23	Artificial Intelligence tools integrating blood biomarkers and radiomics to define lung cancer risk in computed tomography screening programs	Osservazionale con dispositivo	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0201/23	BioPearlTM Microspheres Loaded with Doxorubicin for the Treatment of Unresectable HCC: Prospective, Single Arm, Multi-center, Post-Market Clinical Follow-up Study	Osservazionale con dispositivo	Non applicabile	Profit	Terumo Europe N.V.
INT 0204/23	APACE – feasibility of using Accelerometers to measure Physical Activity in Cancer patients on Early phase clinical trials. A feasibility study evaluating the use of accelerometers to capture physical activity levels in cancer patients on early phase clinical trials	Osservazionale con dispositivo	Non applicabile	No Profit	Università di Manchester
INT 0287/23	Bone Marrow-on-Chip: un sensore di recidiva precoce nel tumore del polmone (BuonMarrow):	Osservazionale con dispositivo	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)

Identificativo	Titolo	Tipo	Fase	Promotore	Promotore
INT 0026/22	PROACT 2.0, a new Mobile App to enhance engagement and communication with patients participating in early oncology studies: a feasibility study	Osservazionale con dispositivo	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0007/12	Nimotuzumab and vinorelbina concomitantly to radiation and as maintenance for newly diagnosed diffuse pontine glioma in childhood	Osservazionale biologico	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0153/13	Interaction between clinical and genetic factors in modulation of opioid analgesia and side effects in cancer pain	Osservazionale biologico	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0177/14	Detection of circulating tumor cells and ct DNA blood levels in patients with advanced intra- and extra-hepatic cholangiocarcinoma and evaluation of their changes during treatment	Osservazionale biologico	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0004/15	Prospective study for the determination of the molecular profile of resistance to "target therapies" in patients with solid tumors - Protocol PROFILING	Osservazionale biologico	Non applicabile	No Profit	Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo (TO)
INT 0120/15	A multicenter, translational study to investigate the genomic landscape of cancer of unknown primary (CUP): AGNOSTOS PROFILING study	Osservazionale biologico	Non applicabile	No Profit	Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo (TO)
INT 0131/16	Dedifferentiated retroperitoneal liposarcoma: developing in vitro and in vivo models to understand tumor biology and pre-clinically evaluate novel therapeutic strategies	Osservazionale biologico	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0137/21	DICER1-associated central nervous system sarcoma: molecular and genetic characterization	Osservazionale biologico	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0040/23	Tackling immunomodulatory properties of stromal cells to improve therapeutic strategies in lung cancer	Osservazionale biologico	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0023/15	Evaluation of MGMT promoter methylation status and clinical benefit from therapy based on temozolomide for advanced Ewing's sarcoma	Osservazionale biologico	Non applicabile	No Profit	Istituto Ortopedico Rizzoli
INT 0066/15	Identification of circulating markers for early diagnosis of breast carcinoma	Osservazionale biologico	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0148/15	Circulating miRNA and sensitivity to gemcitabine in patients with metastatic breast cancer	Osservazionale biologico	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0199/15	Monitoring disease progression in triple negative breast cancers by profiling liquid biopsies and tumor lesions	Osservazionale biologico	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
INT 0115/19	Assessing the spatial heterogeneity in ovarian cancer : a focus on MirOvaR prognostic signature	Osservazionale biologico	Non applicabile	No Profit	Fondazione IRCCS Istituto Nazionale dei Tumori (MI)